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Abstract	  
Introduction	  	  
Radical	  Cystoprostatectomy	  (RC)	  is	  a	  major	  surgery	  for	  the	  treatment	  of	  muscle-­‐
invasive	  urinary	  bladder	  cancer	  with	  high	  postoperative	  complication	  rates.	  Evidence	  
suggests	  surgeries	  such	  as	  RC	  induce	  arginine	  deficiency,	  leading	  to	  immunosuppression	  
and	  morbidity.	  The	  supplementation	  of	  specialized	  immunonutrition	  (SIM),	  containing	  L-­‐
arginine,	  omega-­‐3	  fatty	  acids,	  RNA	  nucleotides,	  and	  vitamin	  A,	  has	  shown	  to	  improve	  
postoperative	  outcomes	  in	  other	  surgical	  cohorts.	  The	  purpose	  of	  this	  project	  is	  to	  
investigate	  the	  effects	  of	  perioperative	  SIM	  to	  meet	  nutrient	  demands	  and	  improve	  
outcomes	  following	  RC.	  
Methods	  
	   Men	  undergoing	  RC	  at	  the	  University	  of	  Kansas	  Hospital	  (KUH)	  were	  randomized	  to	  
receive	  either	  SIM	  (Impact	  Advanced	  Recovery®)	  or	  the	  oral	  nutrition	  supplement	  (ONS,	  
Boost	  Plus®)	  drink.	  The	  study	  participants	  were	  blind	  to	  the	  intervention	  and	  consumed	  
the	  supplements	  5	  days	  before	  and	  after	  surgery.	  Plasma	  arginine,	  citrulline,	  and	  ornithine	  
concentrations	  were	  measured	  at	  days	  -­‐6,	  0,	  2,	  14,	  and	  30.	  Early	  (0-­‐30	  days)	  and	  late	  (31-­‐
90	  days)	  complications	  were	  graded	  based	  on	  the	  Clavien-­‐Dindo	  scheme.	  	  Fisher’s	  exact	  
tests,	  T-­‐tests,	  and	  linear	  mixed	  effect	  models	  were	  used	  to	  detect	  differences	  in	  outcomes.	   	  
Results	  
	   The	  SIM	  and	  ONS	  groups	  experienced	  71%	  and	  73%	  early	  complication	  rates	  (P	  =	  
1),	  and	  14%	  and	  43%	  late	  complication	  rates	  (P	  =	  0.21),	  respectively.	  The	  SIM	  group	  had	  a	  
non-­‐significantly	  lower	  rate	  of	  antibiotic	  use	  in	  the	  late	  period	  (14%)	  compared	  to	  the	  ONS	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group	  (50%,	  P	  =	  0.10).	  	  Plasma	  arginine	  significantly	  decreased	  from	  baseline	  to	  POD2	  (P	  =	  
0.0003)	  in	  the	  ONS	  group,	  with	  no	  significant	  change	  in	  the	  SIM	  group.	  There	  was	  no	  
significant	  difference	  in	  plasma	  arginine	  and	  citrulline	  concentrations	  between	  the	  two	  
groups	  over	  time	  (P	  >	  0.05).	  There	  was	  a	  significant	  difference	  between	  in	  plasma	  ornithine	  
concentrations	  between	  the	  two	  groups	  over	  time	  (P	  =	  0.04).	  At	  the	  time	  of	  surgery,	  the	  
SIM	  group	  had	  significantly	  higher	  plasma	  ornithine	  compared	  to	  ONS	  (P	  =	  0.001).	  	  
Conclusion	  
The	  perioperative	  supplementation	  of	  SIM	  in	  RC	  patients	  induces	  a	  shift	  in	  
metabolism	  of	  amino	  acids	  related	  to	  immune	  function	  and	  wound	  healing.	  Though	  SIM	  
supplementation	  was	  unable	  to	  fully	  replete	  arginine	  status	  by	  surgery,	  the	  
supplementation	  prevented	  a	  further	  depletion	  in	  plasma	  arginine	  following	  surgery.	  The	  
trend	  toward	  lower	  infection	  rates	  in	  the	  SIM	  group	  suggests	  preserved	  immune	  function.	  
A	  greater	  amount	  of	  arginine	  may	  be	  necessary	  to	  fully	  replete	  this	  population	  and	  
optimize	  immune	  function	  following	  surgery.	  Additionally,	  the	  SIM	  supplementation	  
produced	  an	  increase	  in	  plasma	  ornithine	  concentration	  at	  the	  time	  of	  surgery,	  which	  may	  
enhance	  wound	  healing.	  More	  research	  is	  needed	  to	  confirm	  the	  benefits	  of	  SIM	  in	  the	  RC	  
cohort.
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Chapter	  1-­Introduction	  
Urothelial	  bladder	  cancer	  is	  the	  fourth	  leading	  cause	  of	  cancer	  in	  men	  (1).	  Radical	  
cystoprostatectomy	  (RC),	  the	  surgical	  removal	  of	  the	  urinary	  bladder,	  pelvic	  lymph	  nodes,	  
distal	  ureters,	  urethra,	  intrapelvic	  nerves,	  prostate,	  and	  seminal	  vesicles,	  is	  the	  standard	  of	  
care	  treatment	  for	  muscle-­‐invasive	  urinary	  bladder	  cancer	  in	  men	  (2,	  3).	  Unfortunately,	  
surgery	  often	  leads	  to	  muscle	  wasting,	  weight	  loss,	  and	  postoperative	  complications	  (4,	  5).	  
Overall,	  complication	  rates	  of	  up	  to	  64%	  have	  been	  reported	  within	  the	  first	  90	  days	  of	  
surgery,	  with	  gastrointestinal	  and	  infectious	  complications	  being	  the	  most	  common	  (4).	  	  
While	  many	  factors	  may	  contribute	  to	  complications	  following	  RC,	  the	  use	  of	  
Specialized	  Immunonutrition	  (SIM)	  in	  similar	  cohorts	  suggests	  that	  supplementation	  to	  
meet	  the	  unique	  nutritional	  demands	  of	  surgery	  may	  improve	  postoperative	  outcomes.	  
Studies	  of	  gastrointestinal	  surgeries	  found	  a	  decrease	  in	  total	  complications,	  infections,	  and	  
hospital	  length	  of	  stay	  with	  the	  use	  of	  SIM	  (6-­‐10).	  While	  little	  investigation	  has	  been	  done	  
in	  the	  RC	  cohort,	  in	  a	  case-­‐control	  pilot	  study	  of	  RC	  patients,	  Bertrand	  et	  al.	  (11)	  found	  a	  
36.7%	  decrease	  in	  complication	  rates	  with	  preoperative	  SIM,	  including	  a	  significant	  
decrease	  in	  ileus	  and	  infections.	  	  
The	  immunonutrients	  in	  SIM	  include	  L-­‐arginine,	  omega-­‐3	  fatty	  acids,	  vitamin	  A,	  and	  
RNA	  nucleotides.	  While	  each	  of	  these	  immunonutrients	  likely	  has	  pleiotropic	  and	  
synergistic	  effects,	  evidence	  suggests	  L-­‐arginine	  may	  play	  the	  most	  significant	  role.	  
Arginine	  is	  a	  conditionally	  essential	  amino	  acid	  that	  is	  depleted	  following	  physical	  traumas	  
(12-­‐14).	  Though	  the	  exact	  mechanism	  is	  unknown,	  this	  may	  occur	  from	  an	  over-­‐expression	  
of	  arginase	  1	  by	  immature,	  immunosuppressive	  cells	  called	  myeloid-­‐derived	  suppressor	  
cells	  (MDSC)	  (12,	  14).	  The	  arginine	  deficiency	  and	  increase	  in	  MDSC	  and	  arginase	  1	  are	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believed	  to	  contribute	  to	  poor	  adaptive	  immunity	  through	  impaired	  T	  lymphocyte	  function,	  
including	  reduced	  cellular	  memory,	  proliferation,	  and	  cytotoxicity	  (12,	  14).	  Low	  plasma	  
arginine	  may	  also	  increase	  susceptibility	  to	  complications	  due	  to	  its	  role	  in	  wound	  healing,	  
inflammation	  regulation,	  and	  bactericidal	  action,	  and	  has	  been	  termed	  “arginine	  deficiency	  
syndrome”	  (15-­‐17).	  The	  decrease	  in	  intracellular	  arginine	  and	  impaired	  T-­‐cell	  function	  
with	  coinciding	  poor	  adaptive	  immunity	  has	  been	  seen	  in	  vivo	  following	  physical	  injury	  
(14).	  Murine	  models	  that	  suffered	  from	  the	  physical	  injury	  experienced	  greater	  bacterial	  
growth	  and	  mortality	  from	  an	  induced	  infection	  when	  compared	  to	  the	  non-­‐injured	  model.	  
A	  similar	  response	  to	  infection	  was	  seen	  in	  non-­‐injured	  models	  injected	  with	  MDSC	  or	  
arginase	  (14).	  However,	  immune	  function	  was	  restored	  in	  injured	  subjects	  with	  
administration	  of	  an	  arginase	  inhibitor,	  further	  implicating	  arginine’s	  role	  in	  the	  
mechanism	  (14).	  	  	  
Research	  suggests	  supplementation	  can	  restore	  arginine	  status.	  SIM	  
supplementation	  in	  the	  critically	  ill	  has	  shown	  to	  significantly	  increase	  plasma	  arginine	  
after	  7	  days,	  while	  ornithine,	  an	  amino	  acid	  metabolite	  of	  arginine,	  significantly	  increased	  
after	  24-­‐hours	  of	  supplementation.	  This	  indicates	  arginine	  supplementation	  may	  impact	  
metabolism	  even	  prior	  to	  a	  reflection	  in	  plasma	  concentration	  (18).	  In	  vitro,	  arginine	  
improves	  T	  lymphocyte	  function	  previously	  impaired	  by	  MDSC	  exposure	  (12,	  19).	  While	  
Ochoa	  et	  al.	  (20)	  found	  low	  nitric	  oxide	  metabolite	  levels	  in	  trauma	  patients,	  
supplementation	  of	  L-­‐arginine	  has	  also	  shown	  to	  increase	  nitric	  oxide	  production	  and	  
muscle	  viability	  in	  ischemic	  tissue	  in	  porcine	  models	  (21).	  Arginine	  supplementation,	  
therefore,	  may	  prevent	  postsurgical	  complications	  by	  restoring	  immune	  function	  and	  
improving	  wound	  healing.	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Many	  studies	  continue	  to	  show	  the	  benefits	  of	  SIM	  and	  the	  role	  of	  arginine	  in	  trauma	  
recovery;	  however,	  the	  efficacy	  of	  SIM	  to	  meet	  arginine	  demands	  and	  prevent	  
complications	  following	  RC	  has	  yet	  to	  be	  established.	  	  
	  
STATEMENT	  OF	  PURPOSE:	  To	  investigate	  the	  effect	  of	  perioperative	  SIM	  supplementation	  
on	  arginine	  status	  and	  postoperative	  complications	  in	  the	  RC	  cohort.	  
	  
RESEARCH	  QUESTIONS:	  
1. Does	  perioperative	  SIM	  supplementation	  reduce	  the	  quantity	  and/or	  severity	  of	  
postoperative	  complications	  following	  radical	  cystoprostatectomy?	  
2. Does	  perioperative	  SIM	  supplementation	  prevent	  arginine	  deficiency	  (<80	  umol/L)	  
at	  either	  surgery	  or	  postoperative	  day	  2?	  
a. Does	  plasma	  arginine	  at	  the	  time	  of	  surgery	  correlate	  with	  postoperative	  
complications?	  
b. Does	  plasma	  arginine	  at	  postoperative	  day	  2	  correlate	  with	  postoperative	  
complications?	  
3. Does	  perioperative	  SIM	  supplementation	  change	  plasma	  arginine,	  ornithine,	  or	  
citrulline	  levels	  at	  the	  time	  of	  surgery	  or	  postoperative	  day	  2?	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Chapter	  2-­Review	  of	  Literature	  
INTRODUCTION	  
Radical	  cystoprostatectomy,	  considered	  the	  gold	  standard	  for	  muscle-­‐invasive	  
bladder	  cancer	  (2),	  is	  a	  complicated	  procedure	  with	  considerable	  morbidity	  rate,	  seen	  as	  
high	  as	  64%	  in	  the	  first	  90	  days	  (4).	  While	  several	  factors	  contribute	  to	  postoperative	  
complications,	  optimizing	  nutritional	  status	  proximate	  to	  RC	  may	  be	  a	  key	  component	  to	  
improving	  outcomes.	  
The	  nutritional	  needs	  in	  the	  RC	  cohort	  are	  multifaceted.	  Prior	  to	  urologic	  surgeries,	  
16-­‐47%	  of	  patients	  are	  at	  risk	  for	  malnutrition,	  which	  has	  shown	  to	  impact	  complication	  
rates	  (22-­‐24).	  The	  catabolic	  impact	  of	  surgical	  trauma	  increases	  the	  nutrient	  demand,	  
leaving	  patients	  nutritionally	  deplete.	  Theories	  are	  arising	  suggesting	  induced	  
micronutrient	  deficiencies	  impact	  immune	  function	  and	  contribute	  to	  the	  complications	  
following	  surgery	  (12).	  	  
To	  meet	  these	  unique	  nutritional	  needs,	  supplementation	  of	  L-­‐arginine,	  omega-­‐3	  
fatty	  acids,	  vitamin	  A,	  and	  nucleotides	  through	  specialized	  immunonutrition	  (SIM)	  has	  been	  
used	  to	  optimize	  surgical	  recovery	  (25).	  Each	  component	  of	  SIM	  has	  a	  particular	  role;	  
however,	  L-­‐arginine,	  with	  its	  effect	  on	  modulating	  immune	  function,	  may	  be	  the	  most	  
pertinent	  in	  improving	  postoperative	  outcomes.	  	  
Currently,	  there	  is	  a	  gap	  in	  the	  literature	  involving	  the	  use	  of	  SIM	  in	  RC	  patients.	  The	  
nutritional	  needs	  of	  RC	  patients,	  efficacy	  of	  SIM	  in	  similar	  cohorts,	  and	  preliminary	  data	  
supporting	  the	  role	  of	  nutrition	  in	  RC	  outcomes	  give	  evidence	  for	  the	  potential	  use	  of	  SIM	  in	  
this	  cohort	  (11,	  26-­‐28).	  However,	  currently	  the	  data	  for	  SIM	  use	  in	  urology	  are	  lacking	  (26).	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More	  research	  is	  needed	  to	  determine	  the	  effect	  of	  perioperative	  SIM	  on	  improving	  
outcomes	  in	  RC.	  	  
BACKGROUND	  
Urinary	  bladder	  cancer	  is	  among	  the	  most	  common	  malignancies	  in	  the	  United	  
States.	  Urinary	  bladder	  cancer	  is	  the	  fourth	  leading	  cause	  of	  cancer	  incidence	  and	  eighth	  
leading	  cause	  of	  cancer-­‐related	  death	  in	  men	  (1).	  The	  National	  Cancer	  Institute’s	  
Surveillance,	  Epidemiology,	  and	  End	  Points	  Report	  (SEER)	  estimates	  74,000	  new	  cases	  and	  
16,000	  deaths	  related	  to	  urinary	  bladder	  cancer	  in	  2015	  (1).	   	  
Many	  factors	  appear	  to	  increase	  the	  risk	  of	  bladder	  cancer.	  Men	  are	  four	  times	  more	  
likely	  to	  get	  bladder	  cancer	  than	  women	  (29).	  Genetic	  factors,	  particularly	  those	  involved	  in	  
detoxification	  pathways	  such	  as	  genotypic	  variants	  in	  N-­‐acetyltransferase	  and	  glutathione-­‐
s-­‐transferase	  mu	  1	  genes	  increase	  risk	  for	  bladder	  cancer	  (30).	  Smoking	  causes	  about	  half	  
of	  all	  urothelial	  tumors	  with	  a	  fourfold	  increase	  in	  risk	  for	  current	  smokers	  (31).	  	  
Occupational	  exposures	  such	  as	  aromatic	  amines,	  polycyclic	  aromatic	  hydrocarbons,	  and	  
chlorinated	  hydrocarbons	  may	  contribute	  to	  about	  20%	  of	  urothelial	  bladder	  cancers	  (30).	  
Fluid	  intake	  and	  subsequent	  carcinogen	  exposure	  in	  tap	  water	  may	  also	  play	  a	  role,	  but	  
remains	  controversial	  due	  to	  the	  perceived	  benefits	  of	  urine	  dilution	  and	  frequent	  
urination	  (30).	  Exposures	  to	  environmental	  heavy	  metals,	  such	  as	  arsenic	  and	  cadmium,	  
have	  also	  shown	  to	  increase	  bladder	  cancer	  risk	  (32,	  33).	  	  
Bladder	  cancer	  is	  detected	  at	  various	  stages	  and	  severities,	  generating	  varying	  
effects	  on	  treatment	  plan	  and	  prognosis.	  Bladder	  cancer	  is	  staged	  based	  on	  cell	  type,	  depth	  
of	  tissue	  layer	  penetration,	  lymph	  node	  involvement,	  and	  distant	  metastasis.	  For	  superficial	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bladder	  cancer	  confined	  to	  the	  mucosa	  or	  lamina	  propria,	  the	  typical	  regimen	  includes	  
tumor	  resection	  with	  continued	  surveillance	  (2).	  However,	  due	  to	  the	  risk	  of	  progression,	  
many	  patients	  undergo	  intravesical	  therapy	  or	  proceed	  to	  the	  RC	  for	  high-­‐risk	  superficial	  
tumors	  (2).	  Among	  all	  stages,	  there	  is	  a	  77.9%	  survival	  rate	  at	  five	  years	  following	  
diagnosis	  (29).	  This	  survival	  rate	  drops	  to	  70.2%	  for	  invasive	  tumors	  (29).	  Fifty	  percent	  of	  
bladder	  cancer	  cases	  will	  ultimately	  involve	  distant	  metastasis	  following	  surgery.	  For	  this	  
reason	  neoadjuvant	  or	  adjuvant	  chemotherapy	  is	  often	  employed	  increasing	  survival	  rate	  
5.0-­‐6.5%	  (2).	  	  
For	  those	  with	  muscle-­‐invasive	  bladder	  cancer,	  RC	  is	  the	  standard	  treatment	  (2).	  
While	  technical	  variations	  exist,	  RC	  typically	  involves	  extraction	  of	  the	  urinary	  bladder,	  
pelvic	  lymph	  nodes,	  distal	  ureters,	  urethra,	  intrapelvic	  nerves,	  prostate,	  and	  seminal	  
vesicles	  in	  men	  (3).	  Urinary	  diversions	  can	  be	  either	  incontinent,	  commonly	  the	  ileal	  
conduit,	  or	  continent,	  commonly	  orthotopic	  neobladder,	  both	  requiring	  reconstruction	  of	  
the	  bowel	  (3,	  29,	  34,	  35).	  Following	  surgery,	  patients	  often	  suffer	  from	  urinary	  
incontinence,	  sexual	  dysfunction,	  and	  other	  side	  effects	  impacting	  quality	  of	  life	  (35,	  36).	  
While	  the	  orthotopic	  neobladder	  is	  typically	  the	  favored	  diversion,	  certain	  
contraindications	  such	  as	  positive	  urethral	  margins	  may	  cause	  preference	  to	  the	  quicker	  
and	  easier	  ileal	  conduit	  (35).	  Recently,	  a	  study	  comparing	  the	  two	  diversions	  found	  that	  the	  
neobladder	  led	  to	  improved	  quality	  of	  life	  including	  physical	  and	  social	  functioning	  (37).	  
Among	  all	  techniques,	  the	  mortality	  rate	  following	  RC	  is	  still	  relatively	  high,	  shown	  to	  be	  2	  
and	  7%	  at	  30	  and	  90	  days,	  respectively,	  in	  a	  large	  contemporary	  series	  (38).	  The	  burden	  of	  
bladder	  cancer	  and	  subsequent	  surgery	  gives	  reason	  for	  investigating	  ways	  to	  improve	  
outcomes	  in	  this	  cohort.	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COMPLICATIONS	  TO	  THE	  RADICAL	  CYSTOPROSTATECTOMY	  
While	  many	  different	  complications	  can	  occur,	  gastrointestinal	  and	  infectious	  
complications	  are	  the	  most	  common	  and	  often	  the	  most	  severe	  following	  RC	  (4).	  Shabsigh	  
et	  al.	  (4)	  found	  in	  a	  large	  retrospective	  review	  that	  gastrointestinal	  complications	  occur	  in	  
29%	  of	  patients,	  most	  commonly	  from	  ileus.	  A	  smaller	  study	  confirmed	  ileus	  to	  be	  the	  most	  
common	  minor	  complication,	  contributing	  to	  prolonged	  hospital	  stay	  following	  RC	  and	  
correlating	  with	  a	  higher	  occurrence	  of	  major	  complications	  (39,	  40).	  The	  cohort	  examined	  
by	  Shabsigh	  et	  al.	  also	  found	  a	  quarter	  of	  patients	  experience	  infectious	  complications,	  
including	  urinary	  tract	  infections,	  sepsis,	  and	  wound	  infections	  (4).	  When	  considering	  only	  
the	  more	  severe	  complications,	  gastrointestinal	  and	  infectious	  complications	  continued	  to	  
be	  the	  top	  contributors	  in	  this	  large	  cohort	  (4).	  These	  two	  complications	  are	  also	  
implicated	  in	  cause	  for	  readmissions.	  Readmission	  rates	  in	  the	  first	  90	  days	  following	  RC	  
have	  been	  seen	  at	  26%,	  most	  commonly	  due	  to	  ileus,	  pylonephritis,	  and	  urinary	  tract	  
infection	  (38).	  	  
The	  inflammatory	  response	  following	  RC	  is	  a	  likely	  culprit	  in	  these	  postoperative	  
complications,	  an	  underlying	  mechanism	  in	  both	  ileus	  and	  infection	  (41,	  42).	  The	  systemic	  
inflammatory	  response	  syndrome	  (SIRS)	  is	  non-­‐distinct	  inflammation	  diagnosed	  clinically	  
by	  the	  presence	  of	  two	  or	  more	  of	  the	  following:	  (1)	  fever	  or	  hypothermia,	  (2)	  tachycardia,	  
(3)	  tachypnea,	  (4)	  leukocytosis	  or	  leucopenia	  (43).	  Along	  with	  the	  clinical	  signs,	  SIRS	  is	  
often	  accompanied	  by	  a	  change	  in	  inflammatory	  cytokines	  such	  as	  tumor	  necrosis	  factor	  
(TNF)-­‐α,	  interkeukin	  (IL)-­‐	  1,	  -­‐6,	  and	  -­‐10	  and	  immune	  function	  (44).	  SIRS	  occurs	  at	  a	  higher	  
frequency	  in	  major	  operations	  and	  presence	  beyond	  72-­‐hours	  postoperatively	  has	  been	  
predictive	  of	  complications	  following	  gastrointestinal	  surgery	  (43,	  45).	  A	  significant	  rise	  in	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IL-­‐6	  has	  been	  seen	  following	  RC,	  along	  with	  a	  frequency	  of	  SIRS	  over	  70%	  (44).	  Mitigating	  
this	  inflammatory	  response	  following	  RC	  may	  improve	  immune	  function	  and	  minimize	  
postoperative	  complications.	  	  	  
Grading	  Complications	  
Historically,	  there	  have	  been	  inconsistencies	  in	  reporting	  RC	  complications	  (46).	  
The	  development	  of	  the	  Clavien-­‐Dindo	  grading	  system	  in	  2004	  gave	  the	  surgical	  field	  a	  
mode	  of	  standardized	  reporting	  (47).	  The	  scheme	  grades	  any	  deviation	  from	  the	  ideal	  
postoperative	  course,	  based	  on	  the	  treatment	  severity,	  with	  a	  grading	  scale	  from	  I	  (least	  
severe)	  through	  V	  (death).	  This	  grading	  scheme	  minimizes	  the	  subjectivity	  of	  determining	  
minor	  versus	  major	  complications	  in	  reporting	  surgical	  outcomes.	  Clavien	  et	  al.	  (48)	  
conducted	  a	  study	  five	  years	  following	  the	  proposed	  grading	  system	  evaluating	  the	  use	  and	  
further	  clarifying	  points	  of	  inconsistency.	  The	  authors	  made	  one	  clarification	  to	  move	  away	  
from	  ambiguous	  terms	  such	  as	  “minor”	  and	  “major”	  and	  use	  the	  grading	  scheme	  as	  
originally	  indicated	  without	  variation	  (48).	  The	  lack	  of	  standardized	  reporting	  could	  be	  
reason	  for	  variability	  in	  morbidity	  and	  must	  be	  considered	  when	  reviewing	  the	  literature	  
for	  complications	  in	  RC.	  Using	  the	  standardized	  Clavien-­‐Dindo	  system	  will	  bring	  validity	  
and	  reliability	  to	  reporting	  complications	  in	  the	  RC	  cohort.	  
MALNUTRITION	  AND	  RADICAL	  CYSTOPROSTATECTOMY	  
Following	  major	  surgery,	  such	  as	  RC,	  proper	  wound	  healing	  and	  preservation	  of	  
muscle	  mass	  requires	  adequate	  calories	  and	  protein	  (13).	  Mathur	  et	  al.	  (5)	  reported	  an	  
increased	  caloric	  expenditure	  of	  11%	  above	  expected,	  in	  a	  small	  trial	  in	  men	  two	  weeks	  
following	  RC.	  The	  investigators	  also	  found	  a	  7%	  loss	  in	  total	  body	  protein	  and	  reduced	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muscle	  strength	  at	  the	  same	  time	  point	  (5).	  Six	  months	  later,	  the	  muscle	  strength	  returned	  
completely;	  however,	  only	  63%	  of	  the	  lost	  body	  protein	  was	  regained	  (5).	  Hensle	  et	  al.	  (27)	  
demonstrated	  a	  nitrogen	  loss	  occurs	  following	  RC	  regardless	  of	  nutritional	  support	  (5%	  
dextrose	  versus	  total	  parenteral	  nutrition	  containing	  amino	  acids).	  However,	  the	  nitrogen	  
balance	  was	  restored	  only	  in	  the	  group	  receiving	  amino	  acids	  by	  postoperative	  day	  4.	  The	  
group	  receiving	  5%	  dextrose	  lost	  significantly	  more	  nitrogen	  per	  kilogram	  of	  body	  weight	  
in	  the	  6	  days	  monitored	  in	  the	  trial,	  indicating	  the	  importance	  and	  efficacy	  of	  nutritional	  
support	  in	  body	  protein	  preservation	  (27).	  	  
Due	  to	  the	  catabolic	  response	  of	  the	  surgery,	  nutritional	  status	  prior	  to	  RC	  may	  
affect	  outcomes.	  In	  general,	  malnutrition	  is	  associated	  with	  poor	  surgical	  outcomes	  
including	  an	  increased	  length	  of	  stay,	  elevated	  critical	  care	  admission	  rates,	  prolonged	  
wound	  healing,	  and	  infection	  (13).	  In	  hospitalized	  urologic	  cohorts,	  16-­‐21%	  of	  patients	  are	  
at	  severe	  risk	  of	  being	  malnourished	  (22,	  24),	  with	  higher	  rates,	  33-­‐46%,	  seen	  in	  those	  
undergoing	  RC	  and	  open	  surgeries	  (22,	  23).	  The	  reported	  studies	  utilized	  the	  Nutritional	  
Risk	  Screening	  tool	  that	  assesses	  weight	  loss,	  body	  mass	  index	  (BMI),	  and	  food	  intake	  (22-­‐
24).	  A	  score	  indicating	  high	  risk	  of	  malnutrition	  is	  correlated	  with	  a	  three	  times	  greater	  
likelihood	  for	  complications	  following	  a	  urologic	  surgery	  (23).	  Another	  study	  specifically	  
conducted	  in	  RC	  patients,	  using	  albumin,	  BMI,	  and	  pre-­‐surgical	  weight	  loss,	  found	  19%	  of	  
patients	  are	  malnourished,	  which	  increased	  risk	  for	  early	  (90	  days	  postoperatively)	  
mortality	  and	  predicted	  a	  poor	  3-­‐year	  survival	  rate	  (28).	  These	  studies	  indicate	  the	  need	  
for	  nutritional	  support	  surrounding	  RC	  for	  an	  optimal	  postoperative	  course.	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Measuring	  Malnutrition	  	  	  
Many	  different	  assessments	  are	  used	  in	  determining	  nutritional	  status.	  Body	  mass	  
index,	  recent	  weight	  loss,	  change	  in	  food	  intake,	  and	  preoperative	  albumin	  are	  commonly	  
used	  in	  RC	  cohorts.	  The	  use	  of	  albumin	  as	  a	  nutritional	  marker	  is	  controversial,	  and	  may	  
indicate	  disease	  severity	  rather	  than	  protein	  status	  (49).	  The	  American	  Society	  of	  
Parenteral	  and	  Enteral	  Nutrition	  (ASPEN)	  recommends	  a	  standardized	  system	  for	  
assessing	  nutritional	  status	  in	  oncology	  patients	  using	  weight	  loss,	  estimated	  energy	  
consumption,	  and	  physical	  findings	  (50).	  Several	  assessments	  for	  malnutrition	  including	  
evaluations	  of	  physical	  findings	  have	  been	  validated	  in	  oncology	  patients.	  One	  of	  these	  is	  
the	  patient	  generated-­‐subjective	  global	  assessment	  (PG-­‐SGA).	  The	  PG-­‐SGA	  includes	  
assessing	  depletion	  of	  muscle	  and	  fat	  stores	  as	  well	  as	  fluid	  accumulation	  (51).	  The	  findings	  
from	  the	  PG-­‐SGA	  can	  be	  used	  to	  assess	  malnutrition	  in	  the	  RC	  patients,	  employing	  the	  
ASPEN	  criteria	  to	  draw	  conclusions	  between	  nutritional	  status	  and	  postoperative	  
outcomes.	  
SPECIALIZED	  IMMUNONUTRITION	  
The	  nutritional	  demand	  of	  RC	  extends	  beyond	  the	  need	  for	  calories	  and	  protein.	  The	  
evidence	  of	  catabolism	  following	  RC	  surgery	  presents	  a	  case	  for	  early	  nutrition	  support	  in	  
preventing	  loss	  of	  lean	  mass;	  however,	  administration	  of	  conditionally	  essential	  nutrients	  
through	  specialized	  immunonutrition	  (SIM)	  may	  confer	  added	  benefit	  in	  improving	  
outcomes.	  While	  many	  variations	  of	  immunonutrition	  exist,	  one	  particular	  supplement,	  
Impact	  Advanced	  Recovery®,	  has	  shown	  high	  efficacy	  in	  many	  different	  cohorts.	  The	  
nutrients	  of	  interest	  in	  Impact	  Advanced	  Recovery®	  include	  L-­‐arginine,	  omega-­‐3	  fatty	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acids,	  vitamin	  A,	  and	  nucleotides.	  Animal	  and	  human	  studies	  have	  given	  rise	  to	  proposed	  
mechanisms	  of	  action	  for	  these	  nutrients,	  and	  clinical	  trials	  have	  suggested	  their	  clinical	  
significance	  that	  may	  lead	  to	  improved	  surgical	  outcomes	  in	  RC	  patients.	  
Arginine	  
	   Arginine	  is	  an	  amino	  acid	  made	  endogenously	  and	  in	  sufficient	  supply	  under	  normal	  
conditions.	  The	  average	  daily	  intake	  is	  4-­‐6g;	  however,	  the	  human	  body	  makes	  about	  15-­‐20g	  
per	  day	  through	  the	  citrulline	  intestinal-­‐renal	  axis	  to	  maintain	  plasma	  concentrations	  of	  
80-­‐100	  μmol/L	  (15,	  52).	  Under	  stressful	  conditions	  such	  as	  illness	  or	  following	  a	  major	  
surgery,	  plasma	  levels	  fall,	  therefore	  requiring	  exogenous	  production	  and	  giving	  arginine	  
the	  classification	  as	  a	  conditionally	  essential	  amino	  acid	  (13).	  In	  fact,	  arginine	  depletion	  by	  
50%	  or	  greater	  to	  a	  level	  of	  deficiency	  following	  surgery	  or	  trauma	  has	  been	  reported	  in	  
the	  literature	  (12).	  
Arginine	  is	  mostly	  used	  in	  protein	  synthesis	  for	  cell	  growth	  and	  proliferation;	  
however,	  arginine	  is	  also	  metabolized	  by	  nitric	  oxide	  synthase	  (NOS),	  to	  produce	  nitric	  
oxide	  (NO)	  and	  citrulline,	  and	  arginiase,	  to	  produce	  ornithine	  and	  urea	  (Figure	  1)	  (17,	  52).	  
The	  role	  of	  NO	  is	  differentiated	  by	  the	  synthase	  active	  in	  its	  production.	  Nitric	  oxide	  can	  act	  
as	  a	  neurotransmitter,	  vasodilator,	  or	  immune	  regulator	  to	  kill	  infectious	  pathogens,	  
modulate	  inflammation,	  and	  aid	  in	  T	  lymphocyte	  proliferation	  (15).	  Arginine	  metabolism	  
by	  arginase	  may	  promote	  wound	  healing	  through	  the	  ultimate	  production	  of	  proline	  and	  
polyamines	  from	  ornithine	  (17).	  Both	  of	  the	  major	  enzymes	  for	  arginine	  have	  inducible	  
forms	  that	  are	  active	  in	  response	  to	  different	  T	  helper	  cells	  and	  their	  cytokines,	  
differentiating	  arginine’s	  role	  based	  on	  the	  immune	  state	  of	  the	  body	  (17).	  The	  role	  of	  
arginine	  in	  T	  lymphocyte	  function	  is	  continuing	  to	  be	  studied.	  T	  lymphocytes	  require	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adequate	  arginine	  for	  cellular	  memory,	  production	  of	  membrane	  receptors,	  and	  proper	  cell	  
cycle	  (17,	  53,	  54).	  	  Due	  to	  its	  role	  in	  wound	  healing	  and	  immune	  function,	  inadequate	  
arginine	  may	  leave	  a	  patient	  at	  greater	  susceptibility	  for	  complications.	  
	  
Figure	  1-­	  Arginine	  metabolism.	  NOS=	  nitric	  oxide	  synthase;	  NO=	  nitric	  oxide;	  ARG=	  arginase	  
Zhu	  et	  al.	  (12)	  compiled	  a	  proposed	  mechanism	  of	  action	  of	  arginine	  as	  an	  
immunonutrient	  based	  on	  animal	  trials	  within	  their	  laboratory.	  Based	  on	  their	  findings,	  the	  
depletion	  of	  arginine	  following	  cellular	  stress	  appears	  to	  be	  caused	  by	  its	  increased	  
breakdown,	  and	  can	  be	  observed	  within	  hours	  of	  surgery	  or	  trauma.	  Myeloid	  cells	  increase	  
following	  tremendous	  physical	  stress.	  These	  myeloid	  cells	  are	  unique	  in	  that	  they	  are	  
immature	  and	  over-­‐express	  arginase	  1.	  Under	  normal	  conditions,	  myeloid	  cells	  typically	  do	  
not	  metabolize	  much	  arginine;	  however,	  cellular	  stress	  appears	  to	  activate	  high-­‐affinity	  
cationic	  amino	  acid	  transporters	  that	  shuttle	  arginine	  into	  myeloid	  cells,	  depleting	  its	  
availability	  to	  T	  lymphocytes	  (17).	  These	  myeloid	  cells	  inhibit	  T-­‐cell	  activity	  in	  vitro,	  and	  
may	  be	  cause	  for	  the	  immunosuppression	  following	  trauma	  (19).	  Because	  of	  their	  
immunosuppressive	  activity,	  these	  cells	  that	  over-­‐express	  arginase	  1	  have	  been	  termed	  
	   13	  
myeloid-­‐derived	  suppressor	  cells	  (MDSC)	  (12).	  However,	  the	  inhibition	  on	  T	  lymphocyte	  
function	  is	  reversed	  with	  either	  an	  arginase	  antagonist	  or	  L-­‐arginine	  supplementation,	  
suggesting	  nutritional	  intervention	  may	  restore	  immune	  function	  (19).	  	  	  
Arginine	  may	  also	  have	  specific	  implications	  in	  sepsis,	  which	  would	  be	  of	  interest	  
for	  the	  RC	  cohort.	  During	  sepsis,	  there	  is	  a	  decrease	  in	  plasma	  arginine	  (13).	  Based	  on	  the	  
proposed	  mechanism,	  low	  arginine	  due	  to	  upregulated	  MDSCs	  may	  leave	  an	  individual	  at	  
greater	  susceptibility	  for	  infection	  due	  to	  the	  T	  lymphocyte	  suppression.	  However,	  
inconsistency	  in	  human	  trials	  have	  lead	  to	  controversy	  over	  arginine	  supplementation	  in	  
sepsis	  (52).	  	  
Nutritional	  status	  prior	  to	  injury	  may	  influence	  arginine	  metabolism,	  as	  well.	  A	  
study	  in	  a	  porcine	  model	  showed	  that	  reduced	  caloric	  intake	  prior	  to	  sepsis	  led	  to	  a	  greater	  
decrease	  in	  arginine	  levels,	  nitric	  oxide,	  and	  protein	  synthesis	  compared	  to	  the	  adequately	  
nourished	  group	  (55).	  These	  findings	  suggest	  caloric	  restriction	  may	  worsen	  arginine	  
depletion	  and	  nitric	  oxide	  production,	  potentially	  further	  impairing	  recovery	  after	  trauma.	  
Conversely,	  another	  study	  in	  a	  porcine	  model	  demonstrated	  the	  supplementation	  of	  L-­‐
arginine	  can	  lead	  to	  increased	  nitric	  oxide	  and	  muscle	  viability	  to	  an	  otherwise	  ischemic	  
tissue	  (21).	  Therefore,	  optimizing	  nutritional	  status	  prior	  to	  trauma	  or	  illness	  may	  improve	  
outcomes.	  
The	  depletion	  of	  plasma	  arginine,	  increase	  in	  arginase	  1,	  decrease	  in	  NO	  production,	  
T	  lymphocyte	  dysfunction,	  and	  biological	  consequences	  have	  been	  collectively	  termed	  
arginiase	  deficiency	  syndrome	  (ADS)	  (17,	  54).	  Cancer,	  surgery,	  and	  trauma	  patients	  exhibit	  
signs	  of	  ADS,	  therefore	  becoming	  subjects	  of	  study	  for	  arginine	  supplementation	  (17).	  
Drover	  et	  al	  (9)	  conducted	  a	  meta-­‐analysis	  of	  randomized	  control	  trials	  in	  the	  perioperative	  
	   14	  
supplementation	  of	  arginine	  in	  surgical	  patients.	  Trials	  involving	  arginine	  with	  or	  without	  
other	  nutrients	  were	  included.	  Overall,	  there	  was	  a	  significant	  decrease	  in	  infectious	  
complications	  and	  hospital	  length	  of	  stay	  compared	  to	  controls,	  with	  even	  greater	  efficacy	  
for	  the	  Impact	  formulation	  and	  perioperative	  supplementation	  (9).	  	  
The	  state	  of	  arginine	  deficiency	  following	  a	  surgical	  trauma	  appears	  to	  put	  RC	  
patients	  in	  a	  vulnerable	  state	  for	  morbidity	  from	  infection	  and	  ischemia.	  The	  exogenous	  
intake	  of	  L-­‐arginine	  to	  meet	  the	  increased	  demand	  may	  restore	  immune	  and	  wound	  healing	  
function	  in	  the	  RC	  cohort	  to	  prevent	  postoperative	  complications.	  	  
Omega-­3	  Fatty	  Acids	  
	   Omega-­‐3	  fatty	  acids	  (n-­‐3)	  are	  one	  of	  the	  two	  classes	  of	  fatty	  acids	  required	  from	  
exogenous	  sources.	  There	  are	  three	  different	  n-­‐3s	  of	  metabolic	  importance	  including	  alpha-­‐
linolenic	  acid,	  eicosapentaenoic	  acid	  (EPA),	  and	  doxahexaenoic	  acid	  (DHA).	  Alpha-­‐linolenic	  
acid	  is	  the	  only	  truly	  essential	  n-­‐3	  and	  can	  be	  converted	  to	  the	  EPA	  and	  DHA	  in	  the	  body	  by	  
the	  delta-­‐6	  and	  5	  desaturase	  enzymes.	  However,	  desaturase	  enzymes	  are	  variable	  in	  
conversion	  efficiency,	  making	  EPA	  and	  DHA	  important	  dietary	  constituents	  as	  well	  (56).	  
The	  major	  dietary	  sources	  of	  EPA	  and	  DHA	  are	  fatty	  fish	  such	  as	  mackerel	  or	  salmon	  (57).	  
Fish	  oils	  are	  used	  in	  SIM	  to	  add	  the	  immune-­‐modulating	  n-­‐3.	  
The	  immune-­‐modulating	  effects	  of	  n-­‐3	  are	  likely	  due	  to	  the	  anti-­‐inflammatory	  
effects.	  The	  other	  essential	  class	  of	  fatty	  acids	  are	  omega-­‐6	  fatty	  acids	  (n-­‐6).	  Omega-­‐6	  fatty	  
acids	  have	  mostly	  pro-­‐inflammatory	  effects.	  Fatty	  acids	  of	  both	  families	  are	  embedded	  into	  
cellular	  membranes	  in	  limited	  storage.	  	  During	  times	  of	  cellular	  stress,	  phospholipase	  A2	  
cleaves	  available	  membrane	  fatty	  acids,	  which	  are	  then	  further	  metabolism	  by	  the	  induced	  
cyclooxygenase	  and	  lipoxygenase	  enzymes.	  Arachidonic	  acid	  (AA),	  an	  n-­‐6	  fatty	  acid,	  is	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metabolized	  to	  form	  2	  and	  4	  series	  eicosanoids	  including	  prostaglandins	  E2	  (PGE2),	  which	  
have	  pro-­‐inflammatory	  action.	  Conversely,	  EPA	  is	  metabolized	  to	  the	  3	  and	  5	  series	  
eicosanoids,	  including	  prostaglandin	  E3	  (PGE3).	  The	  3	  and	  5	  series	  eicosanoids	  are	  less	  
inflammatory	  and	  actually	  counteract	  the	  2	  and	  4	  series	  eicosanoids.	  Therefore,	  since	  the	  
two	  types	  of	  fatty	  acids	  compete	  for	  space	  in	  the	  cellular	  membrane	  and	  metabolism	  by	  
common	  enzymes	  to	  produce	  eicosanoids	  of	  counter-­‐effects,	  their	  balance	  is	  crucial	  in	  
determining	  the	  level	  of	  systemic	  inflammation	  (16).	  Additionally,	  the	  EPA	  and	  DHA	  
derivatives,	  protectins	  and	  resolvins,	  may	  reduce	  the	  inflammatory	  phase	  and	  prevent	  the	  
associated	  damage	  (58).	  	  
Omega-­‐3	  fatty	  acids	  may	  have	  action	  in	  conjunction	  with	  arginine	  regarding	  MDSCs.	  
Following	  injury,	  evidence	  suggests	  omega-­‐3	  fatty	  acids	  may	  restrain	  the	  rise	  in	  MDSCs	  
(12).	  While	  all	  prostaglandin	  series	  induce	  arginase	  1,	  PGE3	  does	  so	  markedly	  less	  than	  the	  
n-­‐6	  prostaglandin	  series,	  indicating	  a	  greater	  depletion	  of	  arginine	  from	  the	  metabolism	  of	  
n-­‐6	  compared	  to	  n-­‐3	  in	  response	  to	  cellular	  stress	  (59).	  	  
Optimally,	  n-­‐3	  and	  n-­‐6	  would	  be	  present	  in	  cellular	  membranes	  in	  a	  proper	  ratio	  to	  
allow	  for	  an	  appropriate	  level	  of	  inflammation	  following	  a	  stress	  response.	  However,	  the	  
typical	  consumption	  of	  n-­‐3	  in	  the	  Western	  diet	  of	  less	  than	  0.2g/day	  is	  about	  15-­‐20	  times	  
less	  than	  the	  typical	  n-­‐6	  consumption	  (57).	  Therefore,	  it	  is	  likely	  the	  RC	  patients	  are	  
entering	  surgery	  with	  membrane	  fatty	  acid	  composition	  favoring	  hyperinflammation.	  By	  
supplementing	  omega-­‐3	  fatty	  acids	  perioperatively	  in	  RC	  patients,	  the	  inflammation	  may	  be	  
reduced	  resulting	  in	  fewer	  complications.	  	  
Efficacy	  in	  supplementing	  n-­‐3	  through	  an	  oral	  nutrition	  supplement	  around	  surgery	  
is	  still	  being	  investigated.	  Sorensen	  et	  al.	  (60)	  conducted	  a	  double-­‐blinded	  placebo-­‐
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controlled	  trial	  looking	  at	  perioperative	  n-­‐3	  supplementation	  for	  colorectal	  cancer	  surgery.	  
The	  study	  found	  no	  changes	  in	  complication	  rates	  or	  hospital	  length	  of	  stay	  with	  the	  
intervention.	  However,	  in	  a	  meta-­‐analysis	  of	  SIM	  in	  the	  critically	  ill,	  a	  subgroup	  analysis	  
indicated	  that	  the	  fish	  oil	  containing	  supplements	  had	  added	  benefit	  of	  decreased	  mortality	  
and	  reduced	  length	  of	  stay	  (61).	  Aida	  et	  al.	  (62)	  found	  SIM	  supplementation	  before	  a	  major	  
surgery	  resulted	  in	  higher	  EPA/AA	  ratios,	  reduced	  PGE2	  production,	  and	  ultimately	  a	  lower	  
rate	  of	  infectious	  complications.	  While	  more	  investigation	  is	  necessary	  for	  the	  role	  of	  
omega-­‐3	  fatty	  acids	  in	  improving	  post-­‐surgical	  outcomes,	  this	  evidence	  suggests	  
supplementation	  with	  other	  immune-­‐modulating	  ingredients	  such	  as	  L-­‐arginine	  is	  most	  
efficacious.	  
Nucleotides	  
	   Under	  normal	  conditions,	  the	  body	  produces	  nucleotides	  in	  de	  novo	  production	  or	  
recycles	  them	  from	  cell	  turnover.	  That	  being	  said,	  about	  1-­‐2	  g	  of	  nucleotides	  are	  
additionally	  absorbed	  each	  day	  through	  dietary	  sources	  such	  as	  fruits	  and	  vegetables,	  
organ	  meats,	  seafood,	  and	  dried	  legumes	  (63).	  	  
	   Nucleotides	  have	  many	  functions	  crucial	  for	  growth	  and	  metabolism.	  Nucleotides	  
are	  the	  building	  blocks	  for	  DNA	  and	  RNA	  necessary	  for	  storing	  and	  transferring	  genetic	  
information,	  cellular	  division,	  and	  protein	  synthesis.	  Units	  of	  cellular	  energy,	  adenosine	  
triphosphate	  and	  uridine	  triphosphate,	  are	  both	  made	  of	  nucleotides.	  Additionally,	  
components	  of	  the	  secondary	  messenger	  system	  used	  for	  cell	  signaling	  and	  enzyme	  
regulation,	  cyclic	  adenosine	  monophosphate	  and	  cyclic	  genosine	  monophosphate,	  rely	  on	  
nucleotides	  (63).	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During	  times	  of	  increased	  protein	  demand	  such	  as	  gastrointestinal	  insult,	  rapid	  
growth,	  and	  immunocompromised	  situations,	  nucleotide	  depletion	  may	  occur	  (63).	  For	  this	  
reason,	  it	  has	  been	  said	  that	  nucleotides	  become	  semi-­‐essential	  in	  a	  diseased	  state	  (64).	  
Due	  to	  the	  functional	  role	  of	  nucleotides	  in	  basic	  cellular	  processes,	  inadequate	  availability	  
could	  have	  adverse	  consequences,	  particularly	  in	  cells	  of	  rapid	  turnover	  like	  the	  alimentary	  
tract	  and	  immune	  system	  (63).	  Considering	  the	  high	  proportion	  of	  GI	  and	  infectious	  
complications	  in	  the	  RC	  cohort	  (4),	  maintaining	  nucleotides	  may	  impact	  postoperative	  
outcomes.	  
While	  human	  studies	  of	  nucleotides	  typically	  include	  the	  use	  of	  other	  components	  in	  
SIM,	  many	  animal	  models	  have	  looked	  at	  nucleotides	  specifically.	  In	  one	  study,	  Xu	  et	  al.	  
(64)	  found	  nucleotide	  supplementation	  enhanced	  innate	  and	  acquired	  immunity	  in	  healthy	  
mice.	  	  
Due	  to	  the	  catabolic	  nature	  of	  RC,	  an	  increased	  need	  for	  nucleotides	  following	  
surgery	  is	  likely.	  While	  the	  evidence	  of	  nucleotides	  alone	  in	  affecting	  surgical	  outcomes	  is	  
limited,	  proposed	  mechanistic	  action	  and	  its	  presence	  in	  successful	  SIM	  interventions	  
suggest	  exogenous	  intake	  of	  nucleotides	  may	  improve	  outcomes	  in	  the	  RC	  population.	  
Vitamin	  A	  
	   Vitamin	  A	  is	  a	  fat-­‐soluble	  vitamin	  required	  through	  the	  diet.	  Animal	  sources	  such	  as	  
liver,	  eggs,	  and	  fish	  carry	  the	  preformed	  retinyl	  palmitate.	  Vegetables,	  particularly	  those	  of	  
dark	  green	  and	  deep	  orange	  color,	  contain	  carotenoids	  that	  can	  be	  used	  by	  the	  body	  to	  
synthesize	  retinoic	  acid,	  a	  vitamin	  A	  metabolite	  (65).	  Retinoic	  acid	  and	  beta-­‐carotene	  are	  
found	  in	  SIM.	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   Vitamin	  A	  has	  many	  roles	  pertinent	  to	  surgical	  recovery.	  Vitamin	  A	  plays	  a	  role	  in	  
tissue	  repair	  via	  gene	  regulation	  during	  the	  cell	  cycle,	  as	  demonstrated	  in	  the	  effects	  of	  
retinoic	  acid	  deficiency,	  where	  the	  epithelial	  lining	  becomes	  keratinized.	  Vitamin	  A	  also	  has	  
a	  role	  in	  immunity	  by	  promoting	  T-­‐helper	  2	  cell	  formation.	  For	  this	  reason,	  immune	  
function	  decreases	  during	  deficiency	  (15).	  Retinoic	  acid	  has	  another	  role	  when	  considering	  
again	  the	  presence	  of	  MDSCs	  in	  the	  stress	  response.	  Retinoic	  acid	  appears	  to	  mature	  MDSCs	  
which	  arrests	  their	  inhibition	  on	  T-­‐cells	  (12,	  66).	  
	   Retinoic	  acid	  may	  be	  of	  particular	  interest	  for	  the	  RC	  cohort	  by	  reducing	  urinary	  
tract	  infections.	  The	  addition	  of	  either	  vitamin	  E	  or	  A	  to	  standard	  antibiotic	  treatment	  
brought	  reduced	  renal	  scarring	  in	  children	  with	  acute	  pyelonephritis	  (67).	  Patients	  with	  
recurrent	  lower	  urinary	  tract	  infections	  saw	  a	  reduction	  in	  infections	  after	  adding	  vitamin	  
A	  to	  their	  standard	  antimicrobial	  (68).	  	  
	   The	  evidence	  supporting	  vitamin	  A’s	  role	  in	  immunity,	  particularly	  with	  infections	  
of	  the	  urinary	  tract,	  illustrates	  its	  potential	  efficacy	  in	  reducing	  postoperative	  
complications	  in	  RC	  patients.	  
Specialized	  Immunonutrition	  in	  Surgery	  and	  Infection	  
	   While	  each	  component	  of	  SIM	  offers	  unique	  value	  in	  abating	  inflammation	  and	  
improving	  immunity,	  the	  combination	  of	  them	  into	  one	  formula	  has	  the	  best	  evidence	  for	  
influencing	  outcomes.	  	  
Numerous	  trials	  have	  shown	  the	  efficacy	  of	  SIM	  in	  reducing	  inflammation	  after	  
surgery.	  In	  a	  study	  done	  in	  a	  cardiac	  surgery	  cohort,	  patients	  receiving	  the	  SIM	  showed	  a	  
reduced	  IL-­‐10	  expression	  (69).	  	  A	  blunt	  in	  the	  rise	  of	  Il-­‐6	  from	  L-­‐arginine	  and	  omega-­‐3	  
supplementation	  after	  colorectal	  surgery	  has	  also	  been	  seen	  (70).	  Both	  IL-­‐6	  and	  10	  are	  T	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helper	  2	  cytokines,	  which	  have	  been	  implicated	  as	  induces	  of	  arginase	  1	  (17,	  71).	  
Therefore,	  a	  change	  in	  these	  inflammatory	  markers	  from	  SIM	  may	  lead	  to	  a	  lower	  induction	  
of	  arginase	  1	  and	  a	  subsequent	  favorable	  immune	  response.	  
As	  a	  result	  of	  the	  modulation	  of	  inflammatory	  response,	  SIM	  supplementation	  has	  
shown	  to	  improve	  postoperative	  outcomes.	  Reduction	  in	  hospital	  length	  of	  stay,	  infectious	  
complications,	  and	  overall	  complication	  rates	  have	  been	  seen	  in	  many	  oncologic	  surgical	  
populations,	  including	  pancreatic,	  colorectal,	  and	  stomach	  cohorts	  (72,	  73).	  However,	  due	  
to	  the	  gastrointestinal	  (GI)	  reconstruction	  during	  RC,	  the	  studies	  using	  SIM	  in	  GI	  cohorts	  
may	  be	  the	  most	  relevant.	  Osland	  et	  al.	  (6)	  conducted	  a	  meta-­‐analysis	  of	  immune-­‐
modulating	  nutrition	  in	  major	  elective	  GI	  cancer	  surgeries.	  Twenty-­‐two	  placebo-­‐controlled	  
trials	  were	  included	  with	  11	  using	  the	  SIM	  formulation	  and	  6	  solely	  using	  arginine.	  The	  
study	  found	  a	  significant	  decrease	  in	  infectious	  complications	  and	  hospital	  length	  of	  stay	  
for	  both	  perioperative	  and	  postoperative	  supplementation.	  A	  Cochrane	  review	  of	  GI	  
surgeries	  found	  a	  15%	  reduction	  in	  total	  complications	  and	  13%	  reduction	  in	  infectious	  
complications	  with	  preoperative	  immunonutrition	  compared	  to	  either	  a	  placebo	  or	  
conventional	  management	  (8).	  	  Marimutha	  et	  al.	  (7)	  conducted	  a	  meta-­‐analysis	  over	  
immunonutrition	  in	  major	  open	  GI	  surgeries	  for	  only	  randomized	  control	  trials	  using	  an	  
isocaloric/isonitrogenous	  control.	  The	  investigators	  reported	  a	  significant	  reduction	  in	  
length	  of	  stay	  by	  almost	  two	  days	  and	  a	  35%	  reduction	  in	  postoperative	  complications.	  
Findings	  such	  as	  these	  prompted	  the	  European	  Society	  for	  Parenteral	  and	  Enteral	  Nutrition	  
to	  recommend	  perioperative	  administration	  of	  immune-­‐modulating	  formulas	  for	  neck	  and	  
abdominal	  cancer	  patients	  (74).	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While	  many	  of	  the	  studies	  involving	  SIM	  are	  similar,	  some	  heterogeneity	  exists.	  
Evidence	  supports	  that	  both	  L-­‐arginine	  and	  omega-­‐3	  fatty	  acids	  must	  be	  present	  within	  the	  
supplement	  to	  exert	  the	  postoperative	  benefits	  (25).	  Furthermore,	  there	  is	  higher	  efficacy	  
for	  the	  Impact	  formulation	  as	  compared	  to	  other	  immune-­‐modulating	  formulas	  (25).	  
Additionally,	  when	  stratified	  for	  the	  time	  of	  intervention,	  it	  appears	  perioperative	  
supplementation	  confers	  a	  greater	  reduction	  in	  complication	  rate	  and	  length	  of	  stay	  (7).	  
Therefore,	  perioperative	  supplementation	  with	  a	  complete	  formulation	  during	  course	  may	  
be	  most	  effective	  at	  modulating	  inflammation	  and	  preventing	  complications	  in	  the	  RC	  
cohort.	  
Limitations	  in	  the	  Literature	  
Successful	  findings	  continue	  to	  be	  replicated	  in	  many	  surgical	  or	  critical	  care	  
cohorts;	  however,	  as	  pointed	  out	  in	  the	  review	  of	  literature	  by	  Munbauhal	  et	  al.	  (26),	  data	  
are	  lacking	  for	  the	  use	  of	  SIM	  in	  urology	  cohorts.	  Bertrand	  et	  al.	  (11)	  conducted	  the	  first	  
intervention	  study	  in	  a	  multi-­‐centric	  pilot	  case-­‐control	  study	  with	  preoperative	  SIM	  
supplementation.	  The	  findings	  were	  promising	  with	  a	  postoperative	  complication	  rate	  of	  
40%	  in	  the	  SIM	  group	  compared	  to	  76.7%	  in	  the	  control.	  Additionally,	  there	  was	  an	  
increase	  in	  severity	  of	  complication	  in	  the	  control	  group,	  and	  a	  trend	  in	  a	  decreased	  length	  
of	  stay	  of	  3	  days	  in	  the	  SIM	  group.	  Unfortunately,	  the	  trial	  lacked	  randomized	  placebo	  
control,	  showed	  heterogeneity	  in	  the	  multi-­‐centric	  approach,	  and	  used	  a	  retrospective	  
review	  for	  the	  controls.	  Furthermore,	  the	  intervention	  was	  conducted	  strictly	  
preoperatively,	  and	  nutritional	  status	  was	  not	  measured	  either	  before	  or	  after	  the	  
intervention	  (11).	  For	  this	  reason,	  more	  research	  is	  needed	  in	  the	  use	  of	  perioperative	  SIM	  
supplementation	  in	  the	  RC	  cohort.	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CONCLUSION	  
	   The	  high	  complication	  rate	  following	  RC	  remains	  a	  concern	  to	  be	  addressed	  (4).	  
These	  complications	  may	  be	  worsened	  by	  suboptimal	  nutritional	  status.	  Many	  RC	  patients	  
approach	  surgery	  already	  nutritionally	  deplete.	  The	  catabolic	  surgery	  increases	  the	  need	  
for	  many	  nutrients,	  leading	  to	  deficiencies	  that	  can	  aggravate	  postoperative	  complications.	  
The	  mechanistic	  evidence	  of	  the	  individual	  nutrients	  and	  the	  efficacy	  of	  the	  combined	  
formulation	  show	  great	  promise	  in	  the	  use	  of	  SIM	  to	  restore	  immune	  function	  and	  improve	  
surgical	  outcomes.	  	  The	  investigation	  of	  SIM	  in	  reducing	  postoperative	  complications	  has	  
been	  a	  success	  in	  many	  other	  cohorts;	  however,	  data	  are	  still	  lacking	  for	  the	  RC	  cohort	  (25,	  
26,	  61).	  Due	  to	  the	  nutritional	  need	  of	  the	  patients	  and	  lack	  of	  evidence	  for	  the	  use	  of	  SIM,	  
the	  RC	  cohort	  should	  be	  investigated	  for	  the	  effect	  of	  perioperative	  SIM	  on	  post-­‐surgical	  
outcomes.	  Our	  study	  will	  measure	  the	  ability	  of	  the	  perioperative	  SIM	  supplementation	  to	  
meet	  the	  nutritional	  demands	  of	  RC	  in	  order	  to	  prevent	  postoperative	  complications.	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Chapter	  3-­Methods	  
Study	  Design	  
	   The	  study	  was	  a	  prospective,	  randomized,	  single-­‐blinded	  placebo-­‐controlled	  pilot	  
clinical	  trial.	  The	  study	  took	  place	  at	  the	  University	  of	  Kansas	  Medical	  Center	  between	  
September	  2013	  and	  April	  2015.	  The	  Human	  Subjects	  Committee	  of	  the	  University	  of	  
Kansas	  Medical	  Center	  Institutional	  Review	  Board	  and	  the	  protocol	  review	  monitoring	  
committee	  of	  the	  University	  of	  Kansas	  Cancer	  Center	  approved	  the	  study	  protocol.	  
Individuals	  with	  locally	  advanced	  urothelial	  bladder	  cancer	  scheduled	  for	  radical	  
cystoprostatectomy	  at	  the	  University	  of	  Kansas	  Hospital	  (KUH)	  were	  contacted	  and	  
screened	  for	  eligibility.	  Exclusion	  criteria	  included	  swallowing	  difficulties,	  metastatic	  
disease,	  weight	  loss	  ≥	  10%	  six	  months	  prior	  to	  surgery,	  body	  mass	  index	  (BMI)	  ≤	  18.5,	  
active	  viral	  infections,	  history	  of	  gouty	  arthritis	  or	  uric	  acid	  stones,	  allergies	  to	  milk,	  soy,	  or	  
fish,	  female	  gender,	  undergoing	  cystectomy	  for	  non-­‐bladder	  malignancy,	  and	  presence	  non-­‐
urothelial	  cancer.	  	  Written	  informed	  consent	  was	  obtained	  for	  all	  participants	  prior	  to	  
enrollment.	  
	   Participants	  completed	  study	  visits	  at	  baseline	  and	  postoperative	  days	  (POD)	  14	  and	  
30.	  Data	  for	  the	  patient-­‐generated	  subjective	  global	  assessment	  (PG-­‐SGA)	  (51)	  and	  
Charlson	  comorbidity	  index	  (75)	  were	  gathered	  at	  baseline.	  	  
Supplementation	  
	   Participants	  on	  the	  intervention	  arm	  received	  specialized	  immunonutrition	  (SIM,	  
Impact	  Advanced	  Recovery®)	  nutrition	  drinks,	  and	  those	  on	  placebo	  arm	  received	  the	  iso-­‐
caloric/iso-­‐nitrogenous	  oral	  nutrition	  supplement	  (ONS,	  Boost	  Plus®)	  nutrition	  drink.	  The	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nutrient	  composition	  of	  the	  nutrition	  drinks	  is	  described	  in	  Table	  1.	  The	  study	  team	  
wrapped	  all	  nutrition	  drinks	  in	  opaque	  tape	  to	  preserve	  the	  single	  blinding.	  The	  study	  team	  
administered	  15	  drinks	  to	  each	  participant	  with	  instructions	  to	  consume	  three	  each	  day	  for	  
five	  days	  prior	  to	  surgery.	  Within	  24	  hours	  of	  surgery	  after	  physician	  approval,	  the	  study	  
team	  initiated	  feeding	  with	  the	  nutrition	  drinks.	  Postoperative	  feeding	  began	  with	  60mL	  
boluses	  of	  the	  drinks.	  The	  participants	  received	  a	  total	  of	  15	  drinks	  after	  surgery	  and	  were	  
instructed	  to	  consume	  up	  to	  three	  drinks	  a	  day	  as	  tolerated	  until	  all	  drinks	  were	  finished.	  
The	  study	  team	  visited	  the	  participants	  during	  their	  hospital	  stay	  to	  coach	  patients	  on	  oral	  
consumption	  strategies	  including	  regular	  ambulation.	  Diet	  orders	  were	  placed	  by	  the	  
physician	  team	  and	  advanced	  as	  indicated.	  Per	  study	  protocol,	  KUH	  dietitians	  monitored	  all	  
participants.	  	  
	   Participants	  completed	  diet	  diaries	  detailing	  the	  time	  and	  amounts	  of	  the	  nutrition	  
drink	  consumed,	  along	  with	  any	  side	  effects.	  The	  study	  team	  monitored	  compliance	  by	  
collecting	  the	  diet	  diaries	  along	  with	  the	  nutrition	  drink	  cartons.	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Table	  1-­	  Composition	  of	  nutritional	  supplements1	  
	   Specialized	  Immunonutrition	   Oral	  Nutrition	  Supplement	  
Name	   Impact	  Advanced	  Recovery®	   Boost	  Plus®	  
Energy	  (kcal)	   1020	   1080	  
Protein	  (g)	   54.0	   42.0	  
	  	  	  Arginine	   14.1	   1.8	  
	  	  	  Nitrogen	   8.6	   6.7	  
Fat	  (g)	   27.6	   42.0	  
	  	  	  Omega-­‐3	  fatty	  acids	   3.3	   0.0	  
Carbohydrates	  (g)	   135.0	   135.0	  
	  	  	  Fiber	  (g)	   10.8	   9.0	  
Vitamin	  A	  (IU)2	   5670	   3750	  
RNA	  (g)	   1.2	   0.0	  
1Intake	  reflective	  of	  one	  day	  of	  supplementation	  (711mL)	  
2Includes	  50%	  of	  vitamin	  A	  activity	  from	  beta-­‐carotene	  
Amino	  Acids	  
	   Whole	  blood	  was	  collected	  in	  sodium	  EDTA	  tubes	  at	  baseline	  (greater	  than	  5	  days	  
prior	  to	  surgery),	  3	  hours	  after	  surgical	  incision,	  and	  on	  POD	  2,	  14,	  and	  30.	  Plasma	  was	  
collected	  and	  stored	  at	  -­‐80˚C	  after	  centrifugation	  of	  the	  whole	  blood	  samples	  (180	  x	  g	  for	  5	  
min	  at	  25˚C).	  
	   The	  amino	  acid	  analysis	  was	  performed	  using	  the	  Ultraperformance®	  liquid	  
chromatography	  with	  ultraviolet	  detection	  at	  the	  Institute	  for	  Metabolomic	  Disease,	  Baylor	  
Research	  Institute.	  The	  samples	  were	  analyzed	  in	  two	  batches,	  with	  all	  samples	  from	  a	  
single	  participant	  contained	  within	  the	  same	  batch.	  An	  internal	  control	  was	  used	  for	  
determining	  batch	  variability.	  Interassay	  variability	  was	  between	  1.6	  and	  2.3%	  for	  
arginine,	  2.5	  and	  2.7%	  for	  ornithine.	  Sufficient	  levels	  of	  plasma	  arginine	  were	  defined	  as	  
≥80	  μmol/L	  based	  on	  the	  reference	  range	  80-­‐100	  μmol/L	  (15).	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Postoperative	  Complications	  
	   Following	  surgery,	  participants	  were	  monitored	  using	  the	  KUH	  electronic	  medical	  
record	  for	  postoperative	  complications.	  When	  appropriate,	  outside	  medical	  records	  were	  
requisitioned	  to	  assess	  complications	  treated	  outside	  of	  KUH.	  Early	  (within	  30	  days	  
postoperatively)	  and	  late	  (31-­‐90	  days	  postoperatively)	  complications	  were	  recorded	  and	  
graded	  using	  Clavien-­‐Dindo	  scheme	  as	  described	  in	  Table	  2	  (47).	  All	  complications	  
occurring	  within	  the	  time	  frame	  were	  graded	  regardless	  of	  a	  perceived	  likelihood	  of	  
relationship	  to	  the	  radical	  cystoprostatectomy,	  as	  recommended	  by	  authors	  of	  the	  
classification	  scheme	  (48).	  In	  addition	  to	  grading,	  complications	  were	  defined	  using	  
surgery-­‐specific	  categories	  (ileus,	  deep	  vein	  thrombosis,	  pneumonia,	  wound	  infection,	  
urinary	  tract	  infection,	  return	  to	  operation	  room,	  pulmonary	  embolus,	  myocardial	  
infarction,	  cerebral	  vascular	  accident,	  dehiscence,	  sepsis,	  respiratory	  failure,	  bowel	  leak,	  
urine	  leak,	  small	  bowel	  obstruction,	  death,	  or	  other).	  Postoperative	  ileus	  was	  defined	  as	  a	  
delay	  in	  feeding	  of	  greater	  than	  or	  equal	  to	  five	  days	  postoperatively.	  Infectious	  
complications	  were	  identified	  by	  the	  prescription	  of	  non-­‐prophylactic	  antibiotics.	  
Readmission	  rates	  were	  recorded	  along	  with	  the	  incidence	  of	  systemic	  inflammatory	  
response	  syndrome	  (SIRS)	  as	  defined	  in	  Appendix	  A	  (76).	  Complications	  were	  graded	  and	  
recorded	  under	  the	  advisement	  of	  Dr.	  Eugene	  Lee,	  Assistant	  Professor	  in	  the	  Department	  of	  
Urology	  Surgery.	  Age,	  gender,	  smoking	  history,	  comorbidities,	  and	  pathological	  information	  
pertaining	  to	  participants’	  perioperative	  and	  postoperative	  courses	  were	  recorded	  in	  
REDCap.	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Table	  2	  -­	  Clavien-­Dindo	  grading	  scheme	  for	  the	  classification	  of	  surgical	  complications	  (47)	  
Grades	   Definition	  
Grade	  I	   Any	  deviation	  from	  the	  normal	  postoperative	  course	  without	  the	  need	  
for	  pharmacological	  treatment	  or	  surgical,	  endoscopic	  and	  radiological	  
interventions.	  
Allowed	  therapeutic	  regimens	  are:	  drugs	  as	  antiemetic,	  antipyretics,	  
analgesics	  diuretics,	  electrolytes	  and	  physiotherapy.	  
Grade	  II	   Requiring	  pharmacological	  treatment	  with	  drugs	  other	  than	  such	  
allowed	  for	  grade	  I	  complications.	  Blood	  transfusions	  and	  total	  
parenteral	  nutrition	  are	  also	  included.	  
Grade	  III	   Requiring	  surgical,	  endoscopic	  or	  radiological	  intervention	  
Grade	  IIIa	   Intervention	  not	  under	  general	  anesthesia	  
Grade	  IIIb	   Intervention	  under	  general	  anesthesia	  
Grade	  IV	   Life-­‐threatening	  complications	  (including	  central	  nervous	  system	  
complications)	  requiring	  intermediate	  care	  or	  intensive	  care	  unit	  
management.	  
Grade	  IVa	   Single	  organ	  dysfunction	  (including	  dialysis)	  
Grade	  IVb	   Multi	  organ	  dysfunction	  
Grade	  V	   Death	  of	  a	  patient	  
Suffix	  “d”	   If	  the	  patient	  suffers	  from	  a	  complication	  at	  the	  time	  of	  discharge,	  the	  
suffix	  “d”	  (for	  “disability”)	  is	  added	  to	  the	  respective	  grade	  of	  
complication.	  This	  label	  indicated	  the	  need	  for	  a	  follow	  up	  to	  fully	  
evaluate	  the	  complication.	  
	  
Dietary	  Intake	  
Twenty	  four-­‐hour	  dietary	  recalls	  were	  performed	  at	  baseline	  and	  postoperative	  days	  14	  
and	  30	  (Table	  5).	  The	  intakes	  were	  analyzed	  and	  verified	  using	  the	  Nutrition	  Data	  System	  
for	  Research.	  
Statistical	  Analysis	  
	   Prior	  to	  outcome	  data	  analyses,	  baseline	  characteristics	  were	  summarized	  by	  means	  
and	  standard	  deviations	  for	  numerical	  variables	  and	  by	  percentages	  and	  frequencies	  for	  
categorical	  variables.	  Fisher’s	  exact	  tests	  were	  used	  to	  detect	  the	  differences	  in	  the	  
complication	  rates,	  complication	  grades,	  complication	  types,	  readmission	  rates,	  and	  
arginine	  sufficiency	  between	  groups.	  T-­‐tests	  were	  used	  to	  assess	  the	  differences	  between	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continuous	  variables.	  Logistic	  regression	  was	  used	  to	  look	  at	  the	  association	  between	  
requirement	  of	  antibiotic	  use	  and	  arginine	  levels	  at	  time	  of	  surgery	  and	  POD	  2	  as	  both	  a	  
continuous	  and	  categorical	  (sufficient	  or	  deficient)	  variable.	  Linear	  mixed	  effect	  models	  
with	  repeated	  measure	  were	  used	  to	  analyze	  the	  plasma	  amino	  acids	  over	  5	  time	  points.	  A	  
significance	  level	  of	  P	  <	  0.05	  was	  set	  as	  statistically	  significant.	  Statistical	  analyses	  of	  the	  
data	  were	  performed	  by	  Dr.	  Prabhakar	  Chalise,	  Assistant	  Professor	  in	  the	  Department	  of	  
Biostatistics,	  using	  R	  and	  SAS	  9.4	  software.	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Chapter	  4-­	  Results	  
Baseline	  Characteristics	  
	   Twenty-­‐nine	  subjects	  were	  included	  in	  this	  study;	  14	  subjects	  were	  randomized	  to	  
the	  SIM	  group	  and	  15	  were	  randomized	  to	  the	  ONS	  group	  (Figure	  2).	  Patient	  characteristics	  
are	  given	  (Table	  1).	  Two	  participants	  from	  the	  ONS	  group	  voluntarily	  withdrew	  after	  
completing	  the	  pre-­‐operative	  supplementation	  for	  reasons	  unrelated	  to	  the	  supplement.	  
However,	  any	  allowable	  data	  according	  to	  the	  signed	  consent	  form	  from	  the	  two	  
participants	  were	  included	  in	  analysis.	  One	  participant	  in	  the	  ONS	  group	  is	  excluded	  from	  
current	  analysis	  for	  late	  complications	  since	  he	  had	  yet	  to	  meet	  his	  POD	  90	  by	  the	  time	  of	  
data	  extraction.	  Difficulties	  during	  blood	  draw	  and	  inability	  for	  several	  participants	  to	  
attend	  follow-­‐up	  study	  visits	  (POD	  14	  and	  30)	  limited	  the	  available	  data	  at	  days	  0,	  2,	  14,	  
and	  30;	  total	  number	  of	  participants	  (n)	  is	  given	  for	  each	  data	  set.	  	  
Participants	  in	  the	  SIM	  and	  ONS	  groups	  were	  similar	  in	  age	  (69.6	  and	  68.1	  
respectively).	  The	  two	  groups	  were	  similar	  in	  baseline	  characteristics	  with	  the	  exception	  of	  
BMI	  (Table	  3).	  Participants	  in	  the	  SIM	  group	  had	  a	  lower	  BMI	  compared	  to	  the	  ONS	  group	  
(P	  =	  0.04).	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Figure	  2-­	  Participant	  flow	  chart	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Table	  3.	  Baseline	  characteristics	  of	  participants	  
Characteristic	   SIM	  Group	   ONS	  Group	  
N	   14	   15	  
Age,	  mean	  ±	  SD	   69.6	  ±	  7.1	   68.1	  ±	  8.0	  
Smoking	  status,	  No.	  (%)	   	   	  
	  	  	  	  	  	  Current	  Smoker	   	   4	  (28.6%)	   1	  (6.7%)	  
	  	  	  	  	  	  Former	  Smoker	   9	  (64.3%)	   12	  (80.0%)	  
Clinical	  Stage,	  No.	  (%)1	   	   	  
	  	  	  CIS	   4	  (28.6%)	   8	  (53.3%)	  
	  	  	  Ta	   1	  (7.1%)	   2	  (13.3%)	  
	  	  	  Tis	   0	  (0%)	   2	  (13.3%)	  
	  	  	  T1	   2	  (14.3%)	   4	  (26.7%)	  
	  	  	  T2	  
	  
Charlson	  Comorbidity	  Index	  
12	  (85.7%)	  
	  
4.9	  ±	  0.8	  
7	  (46.7%)	  
	  
5.1	  ±	  1.6	  
Charlson	  Comorbidity	  Index2	   4.9	  ±	  0.8	   5.1	  ±	  1.6	  
Neoadjuvent	  Chemotherapy,	  No.	  (%)	   8	  (57.1%)	   4	  (26.7%)	  
BMI*,	  kg/m2	  ±	  SD	   25.8	  ±	  4.0
	   	  
29.4	  ±	  4.7	  
PG-­‐SGA	  	   6.7	  ±5.2
	   	  
5.5	  ±7.2	  
Urinary	  Diversion	  Type	   	   	  
	  	  	  Neobladder	   3	  (21.4%)	   6	  (60.0%)	  
	  	  	  Ileal	  conduit	   11	  (78.6%)	   9	  (40.0%)	  
BMI	  =	  Body	  Mass	  Index;	  PG-­‐SGA=	  Patient	  Generated	  Subjective	  Global	  Assessment	  
1	  NCCN	  Guidelines	  Version	  1.2014	  Staging	  Bladder	  Cancer	  (AJCC,	  7th	  Ed.,	  2010)	  
2	  Higher	  score	  indicates	  greater	  severity	  of	  comorbid	  conditions	  
*P	  =	  0.04	  
Postoperative	  Complications	  	  
Early	  period	  
	   Early	  complications	  (first	  30	  days)	  occurred	  in	  10	  patients	  (71%)	  within	  the	  SIM	  
group	  and	  11	  patients	  (73%)	  in	  the	  ONS	  group.	  The	  two	  groups	  were	  similar	  for	  rates	  of	  
high-­‐grade	  complications,	  type	  of	  complications	  experienced,	  readmission	  rates,	  and	  SIRS	  
during	  the	  early	  period	  (Table	  4	  and	  Appendix	  B).	  When	  stratified	  by	  highest	  Clavien-­‐Dindo	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grade	  of	  complication,	  there	  were	  no	  significant	  differences	  seen	  between	  the	  groups	  
during	  the	  early	  phase	  (Table	  5).	  
Late	  period	  
	   Late	  complications	  (31-­‐90	  days)	  occurred	  in	  2	  patients	  (14%)	  within	  the	  SIM	  group	  
and	  6	  patients	  (43%)	  in	  the	  ONS	  group	  (P	  =	  0.21).	  Within	  the	  ONS	  group,	  50%	  of	  
participants	  received	  non-­‐prophylactic	  antibiotics	  compared	  to	  14%	  in	  the	  SIM	  group	  (P	  =	  
0.10).	  The	  two	  groups	  were	  statistically	  similar	  for	  rates	  of	  high-­‐grade	  complications	  and	  
type	  of	  complications	  experienced	  during	  the	  late	  period	  (Table	  4	  and	  Appendix	  B).	  When	  
stratified	  by	  highest	  Clavien-­‐Dindo	  grade	  of	  complication,	  there	  were	  no	  significant	  
differences	  seen	  between	  the	  groups	  during	  the	  late	  phase	  (Table	  5).	  
Overall,	  complications	  occurred	  in	  75.9%	  of	  participants	  in	  the	  90	  days	  following	  
surgery,	  with	  no	  participant	  deaths.	  Total	  length	  of	  stay	  for	  the	  SIM	  and	  ONS	  group	  was	  
similar	  (6.3	  and	  6.1,	  respectively,	  P	  =	  0.84).	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Table	  4	  -­	  Postoperative	  complications	  




Complications,	  No.	  (%)	  	   	   	   	  
	  	  30	  day	   10	  (71.4%)	   11	  (73.3%)	   1	  
	  	  90	  day	   2	  (14.3%)	   6	  (42.8%)	   0.21	  
High-­‐Grade	  Complications1,	  No.	  (%)	   	   	   	  
	  	  30	  day	   2	  (14.3%)	   2	  (13.3%)	   1	  
	  	  90	  day	   0	  (0%)	   2	  (14.3%)	   0.48	  
Antibiotic	  Use2,	  No.	  (%)	   	   	   	  
	  	  30	  day	   	   5	  (35.7%)	   9	  (60.0%)	   0.27	  
	  	  90	  day	   2	  (14.3%)	   7	  (50.0%)	   0.10	  
Intra-­‐abdominal	  Infection,	  No.	  (%)	   	   	   	  
	  	  30	  day	   1	  (7.1%)	   3	  (20.0%)	   0.33	  
	  	  90	  day	   0	  (0%)	   1	  (7.1%)	   1	  
Surgical	  Site	  Infection,	  No.	  (%)	   	   	   	  
	  	  30	  day	   0	  (0%)	   1	  (7.1%)	   1	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	   1	  
Ileus3	   	   	   	  
	  	  30	  day	   4	  (28.6%)	   2	  (13.3%)	   0.39	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	   1	  
Length	  of	  Stay,	  days	   6.3	  ±3.1	   6.1	  ±	  1.9	   0.84	  
SIRS3,	  No.	  (%)	   1	  (7.1%)	   2	  (13.3%)	   1	  
Readmission4,	  No.	  (%)	   4	  (28.6%)	   6	  (40.0%)	   0.70	  
1Clavien-­‐Dindo	  grades	  III-­‐V	  
2Non-­‐prophylactic	  
3Delay	  in	  feeding	  of	  greater	  than	  or	  equal	  to	  five	  days	  postoperatively	  
4Systemic	  inflammatory	  response	  syndrome	  beyond	  72	  hours	  after	  surgery	  
5Within	  the	  first	  30	  days	  following	  surgery	  
*n	  =	  14	  for	  SIM	  during	  both	  time	  periods	  
**n	  =15	  and	  14	  for	  30	  day	  and	  90	  day	  time	  periods,	  respectively	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Table	  5-­	  Postoperative	  complications	  by	  Clavien-­Dindo	  grade	  
	   SIM	  Group	   ONS	  Group	  
	  30	  day	   (n	  =	  14)	   (n	  =	  15)	  
	  	  Grade	  0	   4	  (28.6%)	   4	  (26.7%)	  
	  	  Grade	  I	   1	  (7.1%)	   0	  (0%)	  
	  	  Grade	  II	   7	  (50%)	   9	  (60.0%)	  
	  	  Grade	  III-­‐a	   1	  (7.1%)	   1	  (6.7%)	  
	  	  Grade	  III-­‐b	   0	  (0%)	   1	  (6.7%)	  
	  	  Grade	  IV-­‐a	   0	  (0%)	   0	  (0%)	  
	  	  Grade	  IV-­‐b	   1	  (7.1%)	   0	  (0%)	  
	  	  Grade	  V	   0	  (0%)	   0	  (0%)	  
90	  Day	   (n	  =	  14)	   (n	  =	  14)	  
	  	  Grade	  0	   12	  (85.7%)	   8	  (57.1%)	  
	  	  Grade	  I	   0	  (0)	   0	  (0)	  
	  	  Grade	  II	   2	  (14.3%)	   4	  (28.6%)	  
	  	  Grade	  III-­‐a	   0	  (0%)	   2	  (14.3%)	  
	  	  Grade	  III-­‐b	   0	  (0)	   0	  (0)	  
	  	  Grade	  IV-­‐a	   0	  (0)	   0	  (0)	  
	  	  Grade	  IV-­‐b	   0	  (0)	   0	  (0)	  
	  	  Grade	  V	   0	  (0)	   0	  (0)	  
	  
Dietary	  Intake	  
Dietary	  intake	  of	  total	  energy,	  protein,	  arginine,	  EPA,	  or	  DHA	  was	  similar	  between	  
the	  two	  groups	  at	  each	  of	  the	  time	  points	  (Table	  6).	  The	  ONS	  group	  had	  a	  significantly	  
lower	  intake	  of	  vitamin	  A	  at	  POD	  14	  compared	  to	  the	  SIM	  group	  (P	  =	  0.03).	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Table	  6-­	  Nutrient	  intake	  
	   SIM	  Group,	  mean	  ±	  SD	  
(n)	  
ONS	  Group	  mean	  ±	  SD	  
(n)	  
Energy,	  kcal/d	  	   	   	  
	  	  	  Baseline	   2699	  ±	  876	  (14)	   2151	  ±	  941	  (15)	  
	  	  	  POD	  14	   2323	  ±	  925	  (9)	  	   1442	  ±	  942	  (5)	  
	  	  	  POD	  30	   2660	  ±	  1263	  (10)	  	   2248	  ±	  608	  (10)	  
Total	  Protein,	  g/d	   	   	  
	  	  	  Baseline	   101	  ±	  38	  (14)	   84	  ±	  36	  (15)	  
	  	  	  POD	  14	  	   85	  ±	  37	  (9)	   73	  ±	  55	  (5)	  
	  	  	  POD	  30	   97	  ±	  45	  (10)	   88	  ±	  29	  (10)	  
Arginine	  Intake,	  g/d	  	   	   	  
	  	  	  Baseline	   5.2	  ±	  2.2	  (14)	   4.5	  ±	  2.2	  (15)	  
	  	  	  POD	  14	   4.4	  ±	  2.2	  (9)	   4.0	  ±	  3.4	  (5)	  
	  	  	  POD	  30	   5.1	  ±	  2.4	  (10)	   4.9	  ±	  1.8	  (10)	  
Vitamin	  A,	  IU/d	   	   	  
	  	  	  Baseline	   6662	  ±	  7179	  (14)	   11392	  ±	  10975	  (15)	  
	  	  	  POD	  14*	  
	  	  
12653	  ±	  11604	  (9)	   2945	  ±	  2356	  (5)	  
	  	  	  POD	  30	   6183	  ±	  7236	  (10)	   5909	  ±	  4746(10)	  
EPA,	  g/d	   	   	  
	  	  	  Baseline	   0.01	  ±	  0.01	  (14)	   0.01	  ±	  0.01	  (15)	  
	  	  	  POD	  14	   0.11	  ±	  0.30	  (9)	   0.01	  ±	  0.01	  (5)	  
	  	  	  POD	  30	   0.01	  ±	  0.02	  (10)	   0.02	  ±	  0.01	  (10)	  
DHA,	  g/d	   	   	  
	  	  	  Baseline	   0.04	  ±	  0.04	  (14)	   0.03	  ±	  0.03	  (15)	  
	  	  	  POD	  14	   0.15	  ±	  0.31	  (9)	   0.07	  ±	  0.07	  (5)	  
	  	  	  POD	  30	   0.03	  ±	  0.04	  (10)	   0.05	  ±	  0.06	  (10)	  
1Based	  on	  24-­‐hour	  dietary	  recall	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Amino	  Acids	  
Arginine	  deficiency	  
At	  the	  time	  of	  surgery,	  8	  patients	  in	  the	  SIM	  group	  (61%)	  and	  10	  in	  the	  ONS	  group	  
(67%)	  were	  considered	  arginine	  deficient,	  with	  no	  significant	  difference	  between	  groups	  
(OR	  1.24,	  95%	  CI	  0.20-­‐7.68).	  Two	  days	  following	  surgery,	  11	  participants	  in	  the	  SIM	  group	  
(85%)	  and	  9	  in	  the	  ONS	  group	  (90%)	  were	  arginine	  deficient,	  with	  no	  significant	  difference	  
between	  the	  two	  groups	  (OR	  1.6,	  95%	  CI	  0.07-­‐107.03).	  
Arginine	  and	  infection	  
	   The	  relationship	  between	  plasma	  arginine	  status	  and	  infection	  rate	  (using	  non-­‐
prophylactic	  antibiotic	  use	  as	  the	  surrogate	  marker)	  was	  investigated	  looking	  at	  arginine	  as	  
a	  continuous	  and	  categorical	  (deficient	  or	  sufficient)	  variable.	  	  Plasma	  arginine	  status	  at	  the	  
time	  of	  surgery	  had	  no	  effect	  on	  antibiotic	  usage	  when	  considering	  plasma	  arginine	  as	  a	  
continuous	  (OR	  1.01,	  95%	  CI	  0.98-­‐1.04)	  or	  categorical	  variable	  (OR	  1.88,	  95%	  CI	  0.40-­‐
9.66).	  Similarly,	  plasma	  arginine	  at	  POD	  2	  had	  no	  effect	  on	  antibiotic	  usage	  when	  
considering	  plasma	  arginine	  as	  a	  continuous	  (OR	  0.99,	  95%	  CI	  0.95-­‐1.04)	  or	  categorical	  
variable	  (OR	  0.50,	  95%	  CI	  0.021-­‐6.06).	  	  	  
Arginine	  over	  time	  
	   Arginine	  concentrations	  were	  not	  significantly	  different	  between	  the	  two	  groups	  
over	  time	  (P	  =	  0.72)	  (Figure	  3).	  Plasma	  arginine	  significantly	  decreased	  from	  baseline	  to	  
POD2	  (P	  =	  0.0003)	  and	  significantly	  increased	  from	  baseline	  to	  POD	  30	  (P	  =	  0.002).	  There	  
was	  no	  significant	  change	  in	  plasma	  arginine	  from	  baseline	  to	  any	  time	  point	  in	  the	  SIM	  
group	  (P	  >	  0.05).	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Figure	  3-­	  Plasma	  arginine	  concentrations	  over	  time.	  There	  is	  a	  significant	  decrease	  in	  
plasma	  arginine	  concentrations	  in	  the	  ONS	  group	  from	  baseline	  to	  POD	  2	  (P	  =	  0.003)	  and	  a	  
significant	  increase	  from	  baseline	  to	  POD	  30	  (P	  =	  0.002).	  The	  dotted	  line	  represents	  the	  
bottom	  of	  the	  reference	  range	  for	  plasma	  arginine	  (80	  μmol/L).	  
Ornithine	  
Orninthine	  concentrations	  were	  significantly	  different	  between	  the	  two	  groups	  over	  
time	  (P	  =	  0.04)	  (Figure	  4).	  At	  time	  of	  surgery	  time,	  the	  SIM	  group	  had	  significantly	  higher	  
plasma	  ornithine	  concentrations	  compared	  to	  the	  ONS	  group	  (P	  =	  0.001).	  There	  were	  no	  
significant	  differences	  in	  ornithine	  concentrations	  between	  the	  two	  groups	  at	  POD	  2,	  14,	  
and	  30.	  	  
Within	  the	  ONS	  group,	  a	  significant	  decrease	  in	  plasma	  ornithine	  was	  seen	  from	  
baseline	  to	  surgery	  (P	  =	  0.01)	  and	  POD	  2	  (P	  =	  0.002).	  Conversely,	  a	  significant	  increase	  in	  
plasma	  ornithine	  was	  seen	  from	  baseline	  to	  surgery	  in	  the	  SIM	  group	  (P	  =	  0.03).	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Figure	  4-­	  Plasma	  ornithine	  concentrations	  over	  time.	  Ornithine	  concentrations	  were	  
significantly	  different	  between	  the	  two	  groups	  over	  time	  (P	  =	  0.04).	  The	  two	  groups	  had	  
significantly	  different	  ornithine	  levels	  at	  surgery	  (*P	  =	  0.001).	  The	  control	  group	  had	  a	  
significant	  decrease	  in	  ornithine	  concentrations	  from	  baseline	  to	  surgery	  (P	  =	  0.01)	  and	  POD	  
2	  (P	  =	  0.002).	  The	  SIM	  group	  had	  a	  significant	  increase	  in	  plasma	  ornithine	  from	  baseline	  to	  
surgery	  (P	  =	  0.03).	  	  
Citrulline	  
Citrulline	  concentrations	  were	  not	  significantly	  different	  between	  the	  two	  groups	  
over	  time	  (P	  =	  0.10)	  (Figure	  5).	  Plasma	  citrulline	  decreased	  from	  baseline	  to	  POD	  2	  in	  both	  
the	  ONS	  (P	  =	  0.0006)	  and	  SIM	  (P	  <	  0.0001)	  groups.	  There	  were	  no	  significant	  differences	  in	  
plasma	  citrulline	  between	  baseline	  and	  any	  other	  time	  point	  in	  either	  group.	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Figure	  5-­	  Plasma	  citrulline	  concentrations	  over	  time.	  Both	  groups	  experienced	  a	  significant	  
decrease	  in	  plasma	  citrulline	  at	  POD	  2	  from	  baseline	  (P	  =	  0.0006	  for	  ONS	  and	  P	  <	  0.0001	  for	  
SIM).	  
	  
Chapter	  5-­	  Discussion	  
This	  study	  investigated	  the	  effects	  of	  perioperative	  specialized	  immunonutrition	  
(SIM)	  on	  postoperative	  complications	  and	  plasma	  amino	  acid	  concentrations	  in	  bladder	  
cancer	  patients	  undergoing	  radical	  cystoprostatectomy	  (RC).	  Ours	  was	  the	  first	  placebo-­‐
controlled	  study	  to	  date	  to	  investigate	  SIM	  supplementation	  in	  the	  RC	  cohort.	  The	  findings	  
of	  this	  study	  suggest	  SIM	  supplementation	  alters	  amino	  acid	  metabolism	  and	  produces	  a	  
trend	  toward	  decreased	  postoperative	  infections.	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Postoperative	  complications	  
Participants	  receiving	  SIM	  supplementation	  had	  a	  36%	  reduction	  in	  antibiotic	  use	  
during	  the	  late	  phase	  of	  recovery	  (Table	  4).	  	  This	  reduction	  suggests	  SIM	  supplementation	  
may	  lead	  to	  a	  lower	  rate	  of	  infection,	  which	  was	  reported	  previously	  by	  Bertrand	  et	  al.	  (11).	  
Arginine	  is	  necessary	  for	  proper	  T	  lymphocyte	  function	  (53).	  Therefore,	  arginine	  depletion	  
from	  surgical	  trauma	  may	  contribute	  to	  immunosuppression	  and	  susceptibility	  to	  infection	  
(12,	  54).	  As	  our	  data	  suggest,	  the	  repletion	  of	  arginine	  through	  SIM	  supplementation	  may	  
reduce	  risk	  of	  infection	  during	  recovery.	  
Our	  study	  did	  not	  find	  a	  significant	  decrease	  in	  total	  complications	  with	  SIM	  
supplementation	  (Table	  4),	  in	  contrast	  to	  the	  study	  conducted	  by	  Bertrand	  et	  al.	  (11)	  that	  
found	  a	  37%	  decrease	  in	  complication	  rate	  with	  the	  use	  of	  SIM	  (P	  =	  0.008).	  However,	  the	  
inclusion	  of	  the	  iso-­‐caloric/iso-­‐nitrogenous	  control	  in	  our	  study	  may	  have	  mitigated	  some	  
of	  the	  discrepancies	  in	  complication	  rates	  seen	  by	  Bertrand	  et	  al.	  (11).	  Previously,	  high	  risk	  
of	  malnutrition	  has	  increased	  complication	  rates	  threefold	  in	  urological	  cohorts	  (23).	  The	  
average	  score	  on	  the	  PG-­‐SGA,	  a	  tool	  validated	  in	  oncologic	  populations	  for	  assessing	  
physical	  findings	  of	  malnutrition	  (51),	  were	  6.7	  and	  5.5	  for	  the	  SIM	  and	  ONS	  groups,	  
respectively.	  Based	  on	  PG-­‐SGA	  scoring,	  a	  score	  of	  >5	  suggests	  the	  need	  for	  nutritional	  
intervention	  via	  a	  dietitian.	  Therefore,	  our	  cohort	  entered	  with	  a	  risk	  of	  malnutrition,	  
suggesting	  perioperative	  nutritional	  support	  in	  the	  form	  of	  either	  SIM	  or	  ONS	  could	  reduce	  
complications.	  	  
Postoperative	  ileus	  is	  a	  common	  complication	  following	  RC,	  occurring	  in	  25%	  of	  
patients	  in	  a	  large	  contemporary	  cohort	  (4).	  Our	  study	  saw	  a	  slightly	  lower	  rate	  in	  ileus	  
among	  all	  study	  participants	  (21%)	  with	  no	  significant	  difference	  between	  the	  two	  groups.	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Therefore,	  it	  is	  possible	  that	  early	  feeding,	  as	  employed	  by	  enhanced	  recovery	  after	  surgery	  
(ERAS)	  protocols	  (77),	  may	  reduce	  ileus,	  regardless	  of	  the	  presence	  of	  the	  
immunonutrients.	  Betrand	  et	  al.	  (11)	  reported	  a	  much	  lower	  rate	  of	  ileus	  (7%)	  with	  
preoperative	  SIM,	  but	  had	  identified	  ileus	  at	  postoperative	  day	  7,	  rather	  than	  day	  5.	  	  	  	  	  
The	  morbidity	  rate	  in	  our	  study	  (76%)	  is	  higher	  than	  that	  reported	  in	  the	  literature	  
(64%)	  (4).	  	  However,	  there	  were	  no	  deaths	  in	  our	  cohort	  compared	  to	  the	  previously	  
reported	  90-­‐day	  mortality	  rate	  of	  2-­‐7%	  (4,	  38).	  Furthermore,	  the	  average	  scores	  for	  the	  
Charlson	  comorbidity	  index	  of	  around	  5	  in	  both	  groups	  also	  suggest	  that	  this	  cohort	  may	  
have	  been	  at	  a	  greater	  risk	  for	  complications	  than	  the	  general	  RC	  population.	  	  Rohgmann	  et	  
al.	  (78)	  found	  only	  18%	  of	  a	  contemporary	  European	  RC	  cohort	  scored	  3	  or	  higher	  on	  the	  
Charlson	  comorbidity	  index	  compared	  to	  100%	  of	  our	  cohort.	  Furthermore,	  the	  authors	  
found	  a	  score	  of	  3	  or	  higher	  increased	  risk	  of	  complications	  by	  93%	  (78).	  As	  a	  prestigious	  
oncology	  surgical	  center,	  referrals	  of	  high-­‐risk	  patients	  may	  also	  inflate	  the	  complication	  
rate	  seen	  at	  our	  center.	  	  
Amino	  Acids	  
The	  plasma	  amino	  acid	  analysis	  in	  this	  study	  brings	  a	  new	  contribution	  to	  the	  
literature	  regarding	  SIM	  use	  in	  the	  RC	  cohort.	  This	  data	  brings	  insight	  into	  both	  the	  typical	  
amino	  acid	  metabolism	  surrounding	  RC,	  as	  well	  as	  the	  shift	  caused	  by	  the	  supplementation	  
of	  the	  immunonutrients.	  	  
Arginine	  
Much	  of	  the	  theory	  surrounding	  the	  efficacy	  of	  SIM	  involves	  the	  ability	  of	  the	  
immunonutrient	  supplementation	  to	  prevent	  “arginine	  deficiency	  syndrome”	  (ADS)	  after	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surgery	  (17).	  However,	  our	  data	  revealed	  that	  prior	  to	  surgery,	  the	  RC	  patients	  already	  had	  
arginine	  concentrations	  below	  the	  reference	  range	  (Figure	  3)	  (15).	  Given	  that	  the	  rise	  of	  
MDSCs	  and	  subsequent	  ADS	  have	  been	  implicated	  in	  certain	  cancers	  (17,	  54,	  79),	  it	  is	  
possible	  that	  residual	  tumors	  even	  after	  previous	  resection	  in	  our	  participants	  may	  cause	  
this	  arginine	  deficiency	  at	  baseline.	  Even	  with	  SIM	  supplementation,	  arginine	  levels	  were	  
not	  fully	  replete	  at	  the	  time	  of	  surgery.	  However,	  SIM	  supplementation	  did	  prevent	  further	  
depletion	  of	  arginine	  at	  POD	  2	  that	  was	  seen	  in	  the	  ONS	  group.	  The	  lack	  of	  significant	  
change	  seen	  in	  postoperative	  complications	  may	  be	  related	  to	  the	  inability	  of	  SIM	  to	  fully	  
replete	  arginine	  and	  restore	  immune	  function,	  suggesting	  14g/day	  of	  arginine	  is	  
insufficient	  in	  meeting	  the	  preoperative	  needs	  of	  RC	  patients.	  	  	  
Ornithine	  
Contrary	  to	  the	  expected	  change	  in	  arginine,	  our	  data	  showed	  that	  the	  significant	  
shift	  in	  amino	  acid	  metabolism	  from	  SIM	  occurred	  in	  ornithine	  concentrations	  (Figure	  4).	  	  
Ornithine	  is	  the	  product	  of	  arginine	  metabolism	  by	  arginase.	  Therefore,	  one	  would	  surmise	  
that	  an	  increase	  in	  arginase	  activity	  after	  surgery	  would	  cause	  an	  increase	  in	  ornithine	  
concentration.	  However,	  the	  ONS	  group	  experienced	  a	  decrease	  in	  plasma	  ornithine	  at	  
surgery	  and	  POD	  2.	  Similarly,	  a	  study	  by	  Hol	  et	  al.	  (80)	  reported	  a	  decrease	  in	  plasma	  
ornithine	  from	  the	  beginning	  to	  the	  end	  of	  surgery,	  a	  decrease	  that	  persisted	  for	  24	  hours.	  
Low	  levels	  of	  ornithine	  have	  also	  been	  seen	  following	  trauma	  (18,	  81),	  even	  in	  the	  presence	  
of	  increased	  arginase	  1	  activity	  (81).	  The	  significant	  decrease	  in	  ornithine	  seen	  at	  three	  
hours	  post-­‐incision	  and	  POD	  2	  in	  the	  ONS	  group	  is	  consistent	  with	  these	  findings	  and	  is	  
therefore	  not	  indicative	  of	  a	  decrease	  in	  arginase	  activity,	  but	  likely	  a	  lack	  of	  available	  
substrate,	  arginine.	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Conversely,	  a	  significant	  increase	  in	  plasma	  ornithine	  from	  baseline	  to	  surgery	  
occurred	  in	  the	  SIM	  group.	  Previously,	  Tsuei	  et	  al.	  (18)	  found	  that	  arginine	  
supplementation	  following	  trauma	  is	  metabolized	  to	  ornithine.	  In	  fact,	  plasma	  ornithine	  
concentrations	  increased	  in	  response	  to	  the	  intervention	  six	  days	  prior	  to	  an	  increase	  in	  
plasma	  arginine	  (18).	  Therefore,	  while	  SIM	  produced	  no	  significant	  change	  in	  plasma	  
arginine	  levels	  in	  our	  study,	  the	  change	  in	  ornithine	  does	  reflect	  a	  greater	  availability	  of	  
substrate	  for	  arginase	  activity.	  
The	  implications	  of	  an	  increase	  in	  plasma	  ornithine	  concentrations	  during	  surgery	  
produced	  by	  SIM	  are	  yet	  to	  be	  fully	  elucidated.	  However,	  considering	  ornithine’s	  metabolic	  
pathways,	  such	  increase	  may	  confer	  some	  benefit.	  Ornithine	  is	  metabolized	  into	  by	  
ornithine	  decarboxylase	  and	  ornithine	  aminotransferase	  to	  proline	  and	  polyamines	  (Figure	  
1),	  which	  may	  contribute	  to	  wound	  healing	  through	  collagen	  formation	  and	  cell	  
proliferation	  (17).	  In	  comparing	  the	  amino	  acid	  differences	  surrounding	  major	  and	  minor	  
surgeries,	  Hol	  et	  al.	  (80)	  reported	  ornithine	  levels	  were	  significantly	  lower	  following	  a	  
major	  surgery	  compared	  to	  a	  minor	  surgery,	  while	  the	  arginine	  levels	  did	  not	  differ	  
between	  groups.	  The	  authors	  logically	  concluded	  that	  the	  difference	  in	  ornithine	  
concentrations	  could	  not	  be	  related	  to	  arginase	  activity	  but	  rather	  ornithine	  usage	  for	  
wound	  healing	  (80).	  	  Therefore,	  SIM	  supplementation	  may	  lead	  to	  better	  wound	  healing	  by	  
increasing	  ornithine	  availability	  for	  proline	  and	  polyamine	  production;	  however,	  our	  study	  
neither	  tracked	  nor	  reported	  clinical	  evidence	  to	  this	  effect.	  Furthermore,	  caution	  should	  
be	  used	  when	  interpreting	  the	  increase	  in	  ornithine	  availability	  at	  surgery,	  considering	  no	  
changes	  in	  infection	  rates	  were	  seen	  in	  the	  supplemented	  trauma	  patients	  (18),	  and	  
limiting	  ornithine	  decarboxylase	  activity	  to	  decrease	  cellular	  proliferation	  has	  been	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suggested	  for	  cancer	  therapy	  (82).	  Nevertheless,	  the	  role	  of	  arginine	  supplementation	  for	  
wound	  healing	  through	  proline	  and	  polyamine	  production	  has	  been	  suggested	  previously	  
and	  may	  enhance	  surgical	  recovery	  (83).	  	  	  
Citrulline	  
Regarding	  plasma	  citrulline,	  a	  product	  with	  nitric	  oxide	  (NO)	  of	  arginine	  
metabolism	  and	  a	  precursor	  for	  endogenous	  production	  (Figure	  1),	  both	  groups	  saw	  a	  
significant	  decrease	  at	  POD	  2	  (Figure	  5).	  	  Due	  to	  the	  dual	  role	  of	  citrulline	  in	  arginine	  
metabolism,	  interpretation	  of	  this	  data	  on	  its	  own	  is	  difficult.	  However,	  a	  similar	  decrease	  
in	  plasma	  citrulline	  after	  surgery	  was	  previously	  reported	  along	  with	  a	  decrease	  in	  NO	  
metabolites	  (80).	  Therefore,	  the	  increase	  in	  arginase	  1	  activity	  may	  limit	  arginine	  
availability	  for	  nitric	  oxid	  synthase	  to	  produce	  citrulline	  and	  NO	  following	  surgery.	  Due	  to	  
the	  importance	  of	  NO	  in	  vasodilation	  and	  pathogen	  defense,	  limited	  production	  may	  
contribute	  to	  poor	  outcomes	  following	  RC.	  This	  is	  consistent	  with	  previous	  theories	  
regarding	  the	  metabolic	  consequences	  of	  ADS	  (17),	  suggesting	  the	  SIM	  intervention	  in	  this	  
study	  was	  insufficient	  to	  meet	  all	  the	  metabolic	  needs	  surrounding	  RC.	  	  
Strengths,	  Limitations,	  and	  Future	  Research	  
This	  study	  suggests	  SIM	  may	  reduce	  postoperative	  infections	  and	  induce	  a	  shift	  in	  
amino	  acid	  metabolism	  in	  RC	  patients,	  adding	  to	  the	  literature	  regarding	  this	  cohort.	  
However,	  the	  study	  is	  not	  without	  limitations.	  Most	  notably,	  the	  small	  sample	  size	  made	  
statistical	  significance	  difficult	  to	  achieve.	  Therefore,	  it	  is	  possible	  that	  the	  trend	  toward	  a	  
decrease	  in	  postoperative	  complications	  seen	  with	  SIM	  use	  could	  become	  statistically	  
significant	  in	  a	  larger	  sample.	  While	  conducting	  the	  study	  within	  one	  center	  allowed	  for	  a	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greater	  amount	  of	  control	  over	  protocol	  and	  procedures,	  a	  multi-­‐center	  study	  is	  needed	  for	  
greater	  external	  validity.	  Additionally,	  a	  double-­‐blinded	  design	  would	  maximally	  reduce	  
bias.	  	  
Primary	  to	  this	  study’s	  many	  strengths	  is	  its	  contribution	  as	  the	  first	  randomized-­‐
controlled	  trial	  for	  SIM	  in	  the	  RC	  population.	  The	  iso-­‐caloric/iso-­‐nitrogenous	  ONS	  allowed	  
for	  a	  stronger	  investigation	  of	  the	  immunonutrients	  over	  calories	  and	  protein	  alone.	  
Additionally,	  this	  was	  the	  first	  trial	  to	  supplement	  SIM	  for	  the	  entire	  perioperative	  period.	  
In	  terms	  of	  grading	  the	  complications,	  the	  use	  of	  a	  standardized	  grading	  system	  (Clavien-­‐
Dindo)	  decreased	  subjectivity	  for	  determining	  severity	  level.	  Furthermore,	  the	  use	  of	  non-­‐
prophylactic	  antibiotics	  as	  surrogate	  markers	  for	  infection	  reduced	  ambiguity	  in	  tracking,	  
though	  prescription	  without	  a	  positive	  culture	  could	  have	  inflated	  the	  infection	  rate.	  
Finally,	  this	  study	  combined	  both	  clinical	  outcome	  data	  along	  with	  plasma	  amino	  acids	  in	  
order	  to	  contribute	  to	  the	  literature	  regarding	  the	  etiology	  and	  clinical	  relevance	  of	  SIM	  in	  
the	  RC	  population.	  	  
While	  many	  critical	  components	  were	  included	  in	  study	  outcomes,	  arginase	  1	  
activity	  was	  not	  measured	  and	  could	  be	  useful	  in	  the	  future	  for	  better	  understanding	  the	  
biological	  impact	  of	  SIM.	  Adding	  more	  time	  points	  for	  amino	  acid	  analysis,	  such	  as	  just	  
prior	  to	  surgery,	  could	  help	  differentiate	  the	  impact	  from	  supplementation	  and	  surgery.	  
Employing	  a	  more	  sophisticated	  technique	  for	  tracking	  amino	  acids,	  such	  as	  an	  isotope	  
tracker,	  could	  expand	  the	  understanding	  of	  amino	  acid	  metabolism	  (84).	  Ultimately,	  larger,	  
double-­‐blinded	  trials	  are	  still	  needed.	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Conclusion	  
In	  conclusion,	  the	  perioperative	  supplementation	  of	  SIM	  in	  RC	  patients	  induces	  a	  
shift	  in	  metabolism	  of	  amino	  acids	  that	  are	  related	  to	  immune	  function	  and	  wound	  healing.	  
Even	  prior	  to	  surgery,	  RC	  patients	  have	  low	  plasma	  arginine	  concentrations.	  Though	  SIM	  
supplementation	  was	  unable	  to	  fully	  replete	  arginine	  status	  by	  surgery,	  the	  
supplementation	  prevented	  a	  further	  depletion	  in	  plasma	  arginine	  following	  surgery.	  
Preserving	  arginine	  concentration	  after	  surgery	  by	  the	  supplementation	  of	  SIM	  may	  
prevent	  the	  decline	  in	  immune	  function	  that	  often	  follows	  trauma.	  Our	  data	  present	  
evidence	  to	  this	  effect	  in	  the	  trend	  toward	  lower	  infection	  rates	  seen	  with	  SIM	  
supplementation.	  However,	  a	  greater	  amount	  of	  arginine	  may	  be	  necessary	  to	  fully	  replete	  
this	  population	  and	  optimize	  immune	  function	  following	  surgery.	  The	  greatest	  change	  in	  
amino	  acid	  metabolism	  was	  reflected	  not	  in	  plasma	  arginine	  concentrations,	  however,	  but	  
in	  plasma	  ornithine.	  The	  increased	  concentrations	  of	  ornithine	  during	  surgery	  in	  the	  SIM	  
group	  suggest	  that	  the	  supplemented	  arginine	  is	  metabolized	  to	  ornithine.	  A	  greater	  
availability	  of	  ornithine	  during	  surgery	  recovery	  may	  lead	  to	  greater	  proline	  and	  polyamine	  
production	  for	  enhanced	  wound	  healing.	  However,	  more	  research	  is	  needed	  to	  determine	  
the	  implications	  of	  the	  amino	  acid	  changes	  on	  recovery	  outcomes	  and	  confirm	  the	  benefits	  
of	  perioperative	  SIM	  supplementation	  in	  the	  RC	  cohort.
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Systemic	  inflammatory	  response	  syndrome	  (SIRS)	  criteria	  (43)	  
Category1	   Criteria	  






>20	  breaths/min	  or	  PaCO2	  <4.3	  kPa	  
White	  blood	  cell	  count	  
	  
>12,000	  cells/mm3	  or	  <4000	  cells/mm3	  or	  >10%	  bands	  present	  
1Two	  or	  more	  of	  the	  criteria	  must	  be	  present	  to	  classify	  for	  SIRS	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Postoperative	  complications	  by	  type	  
	   SIM	  Group	   ONS	  Group	  
	  Dehiscence	  	   	   	  
	  	  30	  day	   0	  (0%)	   1	  (6.7%)	  
	  	  90	  day	   0	  (0%)	   1	  (6.7%)	  
Return	  to	  Operating	  Room	   	   	  
	  	  30	  day	   	   0	  (0%)	   1	  (6.7%)	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	  
Pulmonary	  Embolus	   	   	  
	  	  30	  day	   2	  (14.3%)	   0	  (0%)	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	  
Pneumonia	   	   	  
	  	  30	  day	   0	  (0%)	   1	  (6.7%)	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	  
Urinary	  Tract	  Infection	   	   	  
	  	  30	  day	   0	  (0%)	   1	  (6.7%)	  
	  	  90	  day	   2	  (14.3%)	   2	  (14.3%)	  
	  	  	  	  	  	  Pyelonephritis1	   	   	  
	  	  	  	  	  	  	  	  	  30	  day	   0	  (0%)	   1	  (6.7%)	  
	  	  	  	  	  	  	  	  	  90	  day	   0	  (0%)	   2	  (14.3%)	  
Sepsis	   	   	  
	  	  30	  day	   1	  (7.1%)	   1	  (6.7%)	  
	  	  90	  day	   0	  (0%)	   0	  (0%)	  
1Pyelonephritis,	  a	  more	  severe	  form	  of	  urinary	  tract	  infection,	  was	  assessed	  
separately	  as	  an	  outcome,	  but	  counted	  and	  graded	  only	  once	  as	  a	  urinary	  tract	  
infection	  
P	  >	  0.05	  for	  all	  categories	  
	  
	  
	  
	  
	  
